sample.json

[
  {
    "nctId": "NCT01213784",
    "briefTitle": "Optimized Glycemic Control in Heart Failure Patients With DM2:\"Effect on Left Ventricular Function and Skeletal Muscle\"",
    "officialTitle": "Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:\"Effect on Left Ventricular Function and Skeletal Muscle\"",
    "acronym": "HFDM",
    "organization": "University of Aarhus",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 40,
    "leadSponsor": "University of Aarhus",
    "sponsorClass": "OTHER",
    "collaborators": [
      "The Danish Diabetes Association"
    ],
    "conditions": [
      "Type 2 Diabetes",
      "Heart Failure"
    ],
    "interventions": [
      "OTHER: all antidiabetic drugs will be appliable"
    ],
    "briefSummary": "The investigators wish to investigate wether a more strict diabetic control improves cardiac function, muscle strength, exercise capacity and decreases symptoms.\n\nThe investigators hypothesis is that improving the glycemic control in suboptimized diabetics with heart failure will improve cardiac performance, muscle strength, exercise capacity and decrease symptoms.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "90 Years",
    "healthyVolunteers": false,
    "startDate": "2010-09",
    "completionDate": "2012-11",
    "primaryCompletionDate": "2012-11",
    "firstPostedDate": "2010-10-04",
    "lastUpdatePostedDate": "2015-03-06",
    "locations": [
      {
        "facility": "Dept. of cardiology, Aarhus university hospital Skejby",
        "city": "Aarhus",
        "state": "Central Jutland",
        "country": "Denmark"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01213784",
    "scrapedAt": "2026-05-14T17:51:03.369Z"
  },
  {
    "nctId": "NCT03060538",
    "briefTitle": "A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease",
    "officialTitle": "A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease",
    "acronym": null,
    "organization": "Genentech, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 154,
    "leadSponsor": "Genentech, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2",
      "Non-Alcoholic Fatty Liver Disease"
    ],
    "interventions": [
      "DRUG: BFKB8488A",
      "OTHER: Placebo"
    ],
    "briefSummary": "This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to clinic for an optional pre-screening visit.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": false,
    "startDate": "2017-03-05",
    "completionDate": "2019-12-13",
    "primaryCompletionDate": "2019-12-13",
    "firstPostedDate": "2017-02-23",
    "lastUpdatePostedDate": "2020-03-27",
    "locations": [
      {
        "facility": "Pinnacle Research Group Cullman",
        "city": "Anniston",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "Pinnacle Research Group; Llc, Central",
        "city": "Anniston",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "Southern California Research Center, Inc.",
        "city": "Coronado",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Stanford Health Care",
        "city": "Stanford",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Diabetes Research Center",
        "city": "Tustin",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "MD Clinical",
        "city": "Hallandale",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Premier Research Associate, Inc",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Agile Clinical Research Trials",
        "city": "Atlanta",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "MidWest Clinical Research",
        "city": "Overland Park",
        "state": "Kansas",
        "country": "United States"
      },
      {
        "facility": "Hassman Research Institute",
        "city": "Berlin",
        "state": "New Jersey",
        "country": "United States"
      },
      {
        "facility": "Carolina Research Center at Jones Family Practice",
        "city": "Shelby",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "New Orleans Center for Clinical Research",
        "city": "Knoxville",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "Texas Clinical Research Institute, LLC",
        "city": "Arlington",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Dallas Diabetes & Endocrine Center",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Clinical Trials of Texas Incorporated",
        "city": "San Antonio",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Northeast Clinical Research of San Antonio LLC",
        "city": "San Antonio",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Consano Clinical Research",
        "city": "Shavano Park",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "inVentiv Health Clinical",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03060538",
    "scrapedAt": "2026-05-14T17:51:03.463Z"
  },
  {
    "nctId": "NCT02675855",
    "briefTitle": "GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers",
    "officialTitle": "A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers",
    "acronym": null,
    "organization": "Osiris Therapeutics",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 75,
    "leadSponsor": "Osiris Therapeutics",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Foot Ulcer, Diabetic"
    ],
    "interventions": [
      "OTHER: GrafixPRIME®",
      "PROCEDURE: Dressing Application",
      "DEVICE: Off-loading (walking boot)"
    ],
    "briefSummary": "The objective of the study is to compare the efficacy of weekly GrafixPRIME® administration to an Active Comparator in patients with chronic DFUs in a randomized, single-blind study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2016-01",
    "completionDate": "2017-07",
    "primaryCompletionDate": "2017-07",
    "firstPostedDate": "2016-02-05",
    "lastUpdatePostedDate": "2017-07-17",
    "locations": [
      {
        "facility": null,
        "city": "Arizona City",
        "state": "Arizona",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "California City",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "New Mexico",
        "state": "New Mexico",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02675855",
    "scrapedAt": "2026-05-14T17:51:03.504Z"
  },
  {
    "nctId": "NCT01185743",
    "briefTitle": "Antipsychotics and Gene Expression in Soft Tissues",
    "officialTitle": "Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study",
    "acronym": null,
    "organization": "Medical University of Vienna",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 16,
    "leadSponsor": "Medical University of Vienna",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Schizophrenia",
      "Diabetes"
    ],
    "interventions": [
      "DRUG: olanzapine",
      "DRUG: ziprasidone",
      "DRUG: placebo"
    ],
    "briefSummary": "Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.\n\nAim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.",
    "sex": "MALE",
    "minimumAge": "18 Years",
    "maximumAge": "45 Years",
    "healthyVolunteers": true,
    "startDate": "2010-07",
    "completionDate": "2017-01-01",
    "primaryCompletionDate": "2017-01-01",
    "firstPostedDate": "2010-08-20",
    "lastUpdatePostedDate": "2017-03-23",
    "locations": [
      {
        "facility": "Medical University of Vienna",
        "city": "Vienna",
        "state": "State of Vienna",
        "country": "Austria"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01185743",
    "scrapedAt": "2026-05-14T17:51:03.591Z"
  },
  {
    "nctId": "NCT01827735",
    "briefTitle": "Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2",
    "officialTitle": "Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D)",
    "acronym": "DILT1D",
    "organization": "Cambridge University Hospitals NHS Foundation Trust",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "enrollmentCount": 40,
    "leadSponsor": "Cambridge University Hospitals NHS Foundation Trust",
    "sponsorClass": "OTHER",
    "collaborators": [
      "University of Cambridge",
      "Juvenile Diabetes Research Foundation",
      "National Institute for Health Research, United Kingdom",
      "Wellcome Trust"
    ],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: Aldesleukin (Proleukin)"
    ],
    "briefSummary": "Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing pancreatic beta cells thus leading to insulin deficiency and development of hyperglycaemia. Currently, medical management of type 1 diabetes focuses on intensive insulin replacement therapy to limit complications (retinopathy, nephropathy, neuropathy); nevertheless clinical outcomes remain sub optimal. There are intensive efforts to design novel immunotherapies that can arrest the autoimmune process and thereby preserve residual insulin production leading to fewer complications and better clinical outcomes.\n\nThe vast majority of genes that contribute to susceptibility to type 1 diabetes have been found to encode proteins involved in immune regulation and function. In particular, several susceptibility proteins are involved in the interleukin 2 (IL-2) pathway that regulates T cell activation and tolerance to self antigens. Aldesleukin is a human recombinant IL-2 product produced by recombinant DNA technology using genetically engineered E. coli stain containing an analog of the human interleukin-2 gene. There is substantial nonclinical, preclinical and clinical data that ultra low dose IL-2 (aldesleukin) therapy can arrest the autoimmune mediated destruction of pancreatic beta cells by induction of functional T regulatory cells. However, prior to embarking on large proof of concept trials in type 1 diabetes it is essential that the optimum dose of IL-2 (aldesleukin) is determined. The objective of this study is to establish in patients with type 1 diabetes the optimal dose of IL-2 (aldesleukin) to administer in order to increase T regulatory cell response.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "50 Years",
    "healthyVolunteers": false,
    "startDate": "2013-03",
    "completionDate": "2014-05",
    "primaryCompletionDate": "2014-05",
    "firstPostedDate": "2013-04-10",
    "lastUpdatePostedDate": "2015-06-23",
    "locations": [
      {
        "facility": "Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital",
        "city": "Cambridge",
        "state": null,
        "country": "United Kingdom"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01827735",
    "scrapedAt": "2026-05-14T17:51:03.641Z"
  },
  {
    "nctId": "NCT00437008",
    "briefTitle": "Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes",
    "officialTitle": "Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine",
    "acronym": "AGE-Benfo",
    "organization": "Ruhr University of Bochum",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 21,
    "leadSponsor": "Ruhr University of Bochum",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Endothelial Dysfunction",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: Benfotiamine 1050mg, 3 days",
      "BEHAVIORAL: high-AGE vs. low-AGE meal"
    ],
    "briefSummary": "The purpose of the study is to determine whether there are differences in postprandial endothelial function following a high-AGE(Advanced Glycation End-products) meal vs. a low-AGE meal. We also intend to investigate if the therapy with 1050mg Benfotiamine for 3 days protects against the postulated deterioration of endothelial function after a high-AGE meal in people with type 2 diabetes mellitus.",
    "sex": "ALL",
    "minimumAge": "35 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2004-11",
    "completionDate": "2006-01",
    "primaryCompletionDate": null,
    "firstPostedDate": "2007-02-19",
    "lastUpdatePostedDate": "2007-02-19",
    "locations": [
      {
        "facility": "Heart and Diabetes Center NRW",
        "city": "Bad Oeynhausen",
        "state": null,
        "country": "Germany"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00437008",
    "scrapedAt": "2026-05-14T17:51:03.685Z"
  },
  {
    "nctId": "NCT05452525",
    "briefTitle": "Pharmacokinetics and Safety/Tolerability Profile of CKD-379",
    "officialTitle": "A Randomized, Open-label, Single Dose, 3-period, 6-treatment, Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-379 and Coadministration of D759, D745 and D150 in Healthy Subjects",
    "acronym": null,
    "organization": "Chong Kun Dang Pharmaceutical",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 24,
    "leadSponsor": "Chong Kun Dang Pharmaceutical",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Type II Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: CKD-379 I",
      "DRUG: CKD-379 II",
      "DRUG: D759+D745+D150"
    ],
    "briefSummary": "A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "maximumAge": "50 Years",
    "healthyVolunteers": true,
    "startDate": "2022-07-26",
    "completionDate": "2022-09-21",
    "primaryCompletionDate": "2022-08-27",
    "firstPostedDate": "2022-07-11",
    "lastUpdatePostedDate": "2022-10-18",
    "locations": [
      {
        "facility": "Seoul National University Hospital",
        "city": "Seoul",
        "state": "Jongno-gu",
        "country": "South Korea"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05452525",
    "scrapedAt": "2026-05-14T17:51:03.718Z"
  },
  {
    "nctId": "NCT01387425",
    "briefTitle": "Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)",
    "officialTitle": "Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial",
    "acronym": "DIASMOKE",
    "organization": "Universita degli Studi di Catania",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 300,
    "leadSponsor": "Universita degli Studi di Catania",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Smoking Cessation",
      "Diabetes"
    ],
    "interventions": [
      "DRUG: varenicline",
      "DRUG: placebo tablet is made of lactose"
    ],
    "briefSummary": "Objectives\n\nThis protocol is intended to provide information regarding the efficacy and safety of the nicotine partial agonist varenicline tartrate, at a dose of 1 mg twice daily, for smoking cessation in diabetic subjects who smoke. Given that a better understanding of predictors of smoking cessation can be useful in identifying potential quitters and likely relapsers and that little is known about these predictors in diabetics, the role of different predictors of abstinence at the end of the study will also be examined Study Population The study will enroll 150 type 2 diabetic patients (≤ 75 years) who are regular smokers (≥10 cigs/day) and motivated to stop smoking in each of 2 treatment arms (active drug and placebo) Study Design The study is a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of varenicline 1 mg BID in comparison to placebo for smoking cessation. The duration of active treatment will be 12 weeks and subjects will be followed in the nontreatment phase for an additional 12 weeks. This clinical study has an optional research component to prolong the follow up in the nontreatment phase for a full year. Predictors of abstinence at the end of the study will also be examined Study Endpoints Primary Endpoint: Success rates at week 24 in the varenicline vs placebo group. Success rates will be defined as the Continuous Quit Rate since last visit. Subjects will be classified as responders if they are able to maintain abstinence from cigarette smoking during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on the study visit at week 24 Co-primary endpoint: Success rates at week 12 in the varenicline vs placebo group. Success rates will be defined as Continuous Quit Rate for Weeks 8 to 12 of treatment. Subjects will be classified as responders if they are able to maintain complete abstinence from cigarette smoking in each of the last four study visits (week 9, week 10, week 11, and week 12) with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory during the last four study visits (week 9, week 10, week 11, and week 12) confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on each study visit Secondary Endpoint: Success rates at week 52 in the varenicline vs placebo group. Success rates will be defined as the Continuous Quit Rate throughout the last three visits (week 24, week 36, and week 44). Subjects will be classified as responders if they are able to maintain abstinence from cigarette smoking during this period of time with end-expiratory exhaled CO measurements ≤ 10 ppm. This measure will be obtained through reports of cigarette use by means of the Nicotine Use Inventory during the last three study visits (week 24, week 36 and week 44) confirmed by a measurement of an end-expiratory exhaled carbon monoxide concentration that is ≤ 10 ppm on each study visit Additional Measures: Given that a better understanding of predictors of smoking cessation can be useful in identifying potential quitters and likely relapsers and that little is known about these predictors in diabetics, the role of different predictors of abstinence at week 24 and at week 52 will also be examined",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": false,
    "startDate": "2011-06",
    "completionDate": null,
    "primaryCompletionDate": "2015-12",
    "firstPostedDate": "2011-07-04",
    "lastUpdatePostedDate": "2015-12-02",
    "locations": [
      {
        "facility": "Centro per la Prevenzione e Cura del Tabagimso",
        "city": "Catania",
        "state": "Italy",
        "country": "Italy"
      },
      {
        "facility": "Centro per la Prevenzione eCura del Tabagimso",
        "city": "Catania",
        "state": "Italy",
        "country": "Italy"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01387425",
    "scrapedAt": "2026-05-14T17:51:03.761Z"
  },
  {
    "nctId": "NCT06069076",
    "briefTitle": "Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD",
    "officialTitle": "Diagnostic Value of Serum Cathepsin S and Chromogranin A in Diabetic Kidney Disease",
    "acronym": null,
    "organization": "Assiut University",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 92,
    "leadSponsor": "Assiut University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetic Kidney Disease"
    ],
    "interventions": [
      "DIAGNOSTIC_TEST: cathepsin S and chromogranin A"
    ],
    "briefSummary": "1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.\n2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": true,
    "startDate": "2023-11-01",
    "completionDate": "2026-10-01",
    "primaryCompletionDate": "2025-10-01",
    "firstPostedDate": "2023-10-05",
    "lastUpdatePostedDate": "2023-10-13",
    "locations": [],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06069076",
    "scrapedAt": "2026-05-14T17:51:03.813Z"
  },
  {
    "nctId": "NCT04841668",
    "briefTitle": "Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly",
    "officialTitle": "Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly",
    "acronym": "SmartAge",
    "organization": "Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 50,
    "leadSponsor": "Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: Metformin"
    ],
    "briefSummary": "Cognitive disorders increase with age and in the presence of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). In addition, digestive disorders, changes in dietary pattern and decreased activity negatively influence the microbiome.\n\nThe hypothesis is that pharmacological intervention with metformin will modify the composition of the gut microbiota and cognition.\n\nThe study has a pilot longitudinal design, where each patient with T2DM will be followed for one year. Two groups will be recruited:\n\n1. Group A: The aim will be to evaluate the associations between glucose (measured by continuous glucose monitoring (CGM)), cognitive function (by means of cognitive tests and magnetic resonance imaging (MRI)), physical activity (recorded by activity and sleep tracker devicer), metformin, diet (evaluated by nutritional survey) and composition of the microbiota (evaluated by metagenomics), during 12 months (6 months without metformin and 6 months with metformin treatment).\n2. Group B: The aim will be to evaluate the associations between glucose, diet (evaluated by nutritional survey), cognitive function (by means of cognitive tests), physical activity (measured by activity and sleep tracker device), the treatment and composition of the microbiota (evaluated by metagenomics), during 12 months.",
    "sex": "ALL",
    "minimumAge": "65 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2021-04-10",
    "completionDate": "2024-12-03",
    "primaryCompletionDate": "2024-12-03",
    "firstPostedDate": "2021-04-12",
    "lastUpdatePostedDate": "2026-03-31",
    "locations": [
      {
        "facility": "Institut d'Investigació Biomèdica de Girona (IDIBGI)",
        "city": "Girona",
        "state": "Girona",
        "country": "Spain"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04841668",
    "scrapedAt": "2026-05-14T17:51:03.861Z"
  },
  {
    "nctId": "NCT03353376",
    "briefTitle": "Group Versus Individual Care in Diabetes Clinic",
    "officialTitle": "Group Versus Individual Care in Patients With Long Standing Type 1 and Type 2 Diabetes: Non Inferiority in a One Year Prospective Study in a Tertiary Diabetes Clinic",
    "acronym": null,
    "organization": "Rabin Medical Center",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 60,
    "leadSponsor": "Rabin Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus",
      "Group Meetings"
    ],
    "interventions": [
      "BEHAVIORAL: group care with Empowerment model"
    ],
    "briefSummary": "In this prospective, randomized, non blinded, one center (University hospital) trial, 60 patients (28 with type 1 and 32 with type 2 diabetes) with a mean duration of diabetes of 22.5 ± 11.7 years were randomly assigned to group (6 patients per group) or individual usual care for one year. Primary end-point included change in Hba1c and visits to out-patients clinics, secondary endpoint included change in body mass index, blood pressure levels, waist circumference, non HDL Cholesterol, diabetes related and quality of life questionnaires and hospitalizations.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2010-09-13",
    "completionDate": "2014-01-02",
    "primaryCompletionDate": "2014-01-02",
    "firstPostedDate": "2017-11-27",
    "lastUpdatePostedDate": "2017-11-27",
    "locations": [],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03353376",
    "scrapedAt": "2026-05-14T17:51:03.905Z"
  },
  {
    "nctId": "NCT04978974",
    "briefTitle": "Implications of Stress Management Program",
    "officialTitle": "Stress, Coping Strategies and Quality of Life Among Patients With Chronic Conditions: Implications of Stress Management Program",
    "acronym": null,
    "organization": "University of Gujrat",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 110,
    "leadSponsor": "University of Gujrat",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Chronic Conditions, Multiple"
    ],
    "interventions": [
      "BEHAVIORAL: Stress Management Program"
    ],
    "briefSummary": "Previous studies indicated that patients with diabetes mellitus and hypertension had higher level of perceived stress, used maladaptive coping strategies and poor health-related quality of life. Therefore, stress management program was applied to reduce their perceived stress, improve their coping strategies, improve their health-related quality of life and psychological health of the patients with type 2 diabetes mellitus and hypertension in current study. The main objectives of the current study were to observe the effects of stress management program on perceived stress, coping strategies and health-related quality of life using pre-experimental research design. Patients with diabetes mellitus type 2 and hypertension were selected through purposive sampling technique to apply the eclectic approach of the stress management program. Total 110 patients with type 2 diabetes and hypertension completed the program from 114 patients who gave inform consent for participation in the first session. Perceived stress scale, WHOQOL and Coping strategies questionnaire were administered at the pre and post-levels of the program. Further, base line of targeted domains variables was also filled from the participants at pre, mid and post-levels to access the efficacy of the program which was formulated according to previous research data by the researcher. The stress Management program consisted of 10 session which were delivered to eight groups (diabetic and Hypertensive) in five weeks. Each session had the duration 90 minutes and two sessions were conducted in one week.",
    "sex": "ALL",
    "minimumAge": "31 Years",
    "maximumAge": "60 Years",
    "healthyVolunteers": false,
    "startDate": "2019-05-03",
    "completionDate": "2020-12-29",
    "primaryCompletionDate": "2020-01-03",
    "firstPostedDate": "2021-07-27",
    "lastUpdatePostedDate": "2021-07-27",
    "locations": [
      {
        "facility": "Jhelum Poly Clinic",
        "city": "Jhelum",
        "state": "Punjab Province",
        "country": "Pakistan"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04978974",
    "scrapedAt": "2026-05-14T17:51:03.953Z"
  },
  {
    "nctId": "NCT00283218",
    "briefTitle": "A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.",
    "officialTitle": "A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial",
    "acronym": null,
    "organization": "University of Aarhus",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 24,
    "leadSponsor": "University of Aarhus",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Novo Nordisk A/S"
    ],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70"
    ],
    "briefSummary": "The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes.\n\nOBJECTIVE:\n\nThe objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours following a standard test meal on four days respectively in subjects with type 1 diabetes.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2006-01",
    "completionDate": "2006-08",
    "primaryCompletionDate": null,
    "firstPostedDate": "2006-01-27",
    "lastUpdatePostedDate": "2006-08-08",
    "locations": [
      {
        "facility": "Dept of Medicine M, Aarhus University Hospital, Nørrebrogade 44",
        "city": "Aarhus",
        "state": "C",
        "country": "Denmark"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00283218",
    "scrapedAt": "2026-05-14T17:51:04.004Z"
  },
  {
    "nctId": "NCT03819790",
    "briefTitle": "The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians",
    "officialTitle": "Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)",
    "acronym": "VARIATION 2 SA",
    "organization": "LMC Diabetes & Endocrinology Ltd.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 119,
    "leadSponsor": "LMC Diabetes & Endocrinology Ltd.",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: Basal insulin glargine and lixisenatide",
      "DRUG: Basal insulin Basaglar/Lantus + gliclazide MR",
      "DRUG: Metformin"
    ],
    "briefSummary": "The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both added to metformin, on measures of glucose variability using masked CGM data among people of South Asian origin living in Canada with type 2 diabetes (T2DM).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2018-10-02",
    "completionDate": "2019-11-19",
    "primaryCompletionDate": "2019-11-19",
    "firstPostedDate": "2019-01-29",
    "lastUpdatePostedDate": "2021-02-25",
    "locations": [
      {
        "facility": "LMC Brampton",
        "city": "Brampton",
        "state": "Ontario",
        "country": "Canada"
      },
      {
        "facility": "LMC Etobicoke",
        "city": "Etobicoke",
        "state": "Ontario",
        "country": "Canada"
      },
      {
        "facility": "LMC Scarborough",
        "city": "Toronto",
        "state": "Ontario",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03819790",
    "scrapedAt": "2026-05-14T17:51:04.056Z"
  },
  {
    "nctId": "NCT07442110",
    "briefTitle": "This Observational Study Evaluates the Clinical Outcomes of Patients With Diabetes Who Utilize a Specialized Dietary Supplements for Foot Ulcer Healing. The Study Documents the Rate of Complete Wound Closure and the Prevention of Lower Extremity Amputations in a Real-world, At-home Setting.",
    "officialTitle": "Observational Study of a Specialized Dietary Supplements on the Healing of Diabetic Foot Ulcers and Prevention of Amputations",
    "acronym": null,
    "organization": "Amar Zireg",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 35,
    "leadSponsor": "Amar h Zireg",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Self funded"
    ],
    "conditions": [
      "Limb Salvage",
      "Diabetes Complication",
      "Dietary Supplements",
      "Healed Ulcer",
      "Wound Closure",
      "At Home Setting",
      "Diabetes Mellitus, Type 1, Type 2",
      "Wound Healing",
      "Diabetic Foot Ulcer"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Diabetic foot ulcer treatment by dietary supplements"
    ],
    "briefSummary": "This observational study evaluates the clinical outcomes of patients with diabetes who utilize a specialized dietary supplements for foot ulcer healing. The study documents the rate of complete wound closure and the prevention of lower extremity amputations in a real-world, at-home setting.",
    "sex": "ALL",
    "minimumAge": "25 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2025-07-05",
    "completionDate": "2025-09-30",
    "primaryCompletionDate": "2025-09-02",
    "firstPostedDate": "2026-03-02",
    "lastUpdatePostedDate": "2026-03-04",
    "locations": [
      {
        "facility": "Amar hocine Zireg",
        "city": "Bordj Bou Arreridj",
        "state": "Wilaya de Bordj Bou Arréridj",
        "country": "Algeria"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07442110",
    "scrapedAt": "2026-05-14T17:51:04.097Z"
  },
  {
    "nctId": "NCT00643110",
    "briefTitle": "Milk as Treatment for Hypoglycemia",
    "officialTitle": "Milk as Treatment for Hypoglycemia",
    "acronym": null,
    "organization": "Creighton University",
    "overallStatus": "WITHDRAWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 0,
    "leadSponsor": "Creighton University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: D50 glucose"
    ],
    "briefSummary": "Test hypothesis that milk can raise blood sugars as well as orange juice or glucose tablets without raising blood sugars too much the way that orange juice or glucose tablets sometimes do.",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "maximumAge": null,
    "healthyVolunteers": true,
    "startDate": "2008-04",
    "completionDate": "2009-01",
    "primaryCompletionDate": "2009-01",
    "firstPostedDate": "2008-03-26",
    "lastUpdatePostedDate": "2015-03-25",
    "locations": [
      {
        "facility": "Creighton Diabetes Center",
        "city": "Omaha",
        "state": "Nebraska",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00643110",
    "scrapedAt": "2026-05-14T17:51:04.139Z"
  },
  {
    "nctId": "NCT05626413",
    "briefTitle": "Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project",
    "officialTitle": "Cardiovascular Disease and Diabetes in Silesian Patients",
    "acronym": null,
    "organization": "Medical University of Silesia",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 4000,
    "leadSponsor": "Medical University of Silesia",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Silesian University of Technology",
      "Liverpool Heart and Chest Hospital NHS Foundation Trust"
    ],
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [],
    "briefSummary": "The project is an observational one which undertakes different, easy to obtain in everyday clinical practice, demographical, laboratory and clinical parameters of patients with diabetes in Silesian Region in Poland to predict cardiovascular disease, cardiovascular events and neuropathy using machine learning approach.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2015-01-01",
    "completionDate": "2026-01-31",
    "primaryCompletionDate": "2025-12-31",
    "firstPostedDate": "2022-11-23",
    "lastUpdatePostedDate": "2024-04-10",
    "locations": [
      {
        "facility": "Department of Internal Diseases, Diabetology and Nephrology",
        "city": "Zabrze",
        "state": null,
        "country": "Poland"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05626413",
    "scrapedAt": "2026-05-14T17:51:04.171Z"
  },
  {
    "nctId": "NCT04583813",
    "briefTitle": "Empagliflozin and Atrial Fibrillation Treatment",
    "officialTitle": "Efficacy of Empagliflozin in Patients With Heart Failure and Atrial Fibrillation",
    "acronym": "EMPA-AF",
    "organization": "Miulli General Hospital",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 400,
    "leadSponsor": "Miulli General Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Atrial Fibrillation",
      "Heart Failure",
      "Obesity",
      "Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: Empagliflozin",
      "OTHER: Placebo"
    ],
    "briefSummary": "The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2021-09",
    "completionDate": "2024-04",
    "primaryCompletionDate": "2024-01",
    "firstPostedDate": "2020-10-12",
    "lastUpdatePostedDate": "2021-04-02",
    "locations": [
      {
        "facility": "Miulli General Hospital",
        "city": "Acquaviva delle Fonti",
        "state": "Bari",
        "country": "Italy"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04583813",
    "scrapedAt": "2026-05-14T17:51:04.208Z"
  },
  {
    "nctId": "NCT03825926",
    "briefTitle": "Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up",
    "officialTitle": "Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up",
    "acronym": null,
    "organization": "Fifth Affiliated Hospital, Sun Yat-Sen University",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 600,
    "leadSponsor": "Fifth Affiliated Hospital, Sun Yat-Sen University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Gestational Diabetes Mellitus"
    ],
    "interventions": [],
    "briefSummary": "Extraction of whole blood from 10 to 15ml at 24 weeks before pregnancy test, with a view to early detection of GDM, provides evidence for early intervention to improve maternal pregnancy outcomes and metabolic abnormalities.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "50 Years",
    "healthyVolunteers": true,
    "startDate": "2019-06-01",
    "completionDate": "2025-12-01",
    "primaryCompletionDate": "2025-06-01",
    "firstPostedDate": "2019-02-01",
    "lastUpdatePostedDate": "2020-03-31",
    "locations": [
      {
        "facility": "the Fifth Affiliated Hospital of Sun Yat-sen University of Gynaecology and Obstetrics",
        "city": "Zhuhai",
        "state": "Guangdong",
        "country": "China"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03825926",
    "scrapedAt": "2026-05-14T17:51:04.248Z"
  },
  {
    "nctId": "NCT01426685",
    "briefTitle": "Prognosis of Type 2 Diabetic Patients",
    "officialTitle": "Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology",
    "acronym": "ARTEMIS",
    "organization": "University of Oulu",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 1880,
    "leadSponsor": "University of Oulu",
    "sponsorClass": "OTHER",
    "collaborators": [
      "The Finnish Funding Agency for Technology and Innovation"
    ],
    "conditions": [
      "Cardiovascular Risk Assessment"
    ],
    "interventions": [],
    "briefSummary": "The study will include 1200 patients with type 2 diabetes and angiographically documented coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes. Extensive traditional and novel risk marker tests are performed for the patients and they will be followed-up for 5 years. Sudden cardiac death is the main outcome measure and various other endpoints are secondary endpoints. As a substudy, 120 diabetic patients and 120 non-diabetic patients will undergo exercise training with home monitoring to assess the effects of exercise training on risk profiles.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": false,
    "startDate": "2007-08",
    "completionDate": "2019-06",
    "primaryCompletionDate": "2019-06",
    "firstPostedDate": "2011-08-31",
    "lastUpdatePostedDate": "2019-04-19",
    "locations": [
      {
        "facility": "University of Oulu",
        "city": "Oulu",
        "state": null,
        "country": "Finland"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01426685",
    "scrapedAt": "2026-05-14T17:51:04.291Z"
  },
  {
    "nctId": "NCT07395050",
    "briefTitle": "Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes",
    "officialTitle": "A Pilot Study to Evaluate the Safety, Tolerability, and Feasibility of Autologous Anti-CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Stage 3 Type 1 Diabetes",
    "acronym": null,
    "organization": "City of Hope Medical Center",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "EARLY_PHASE1"
    ],
    "enrollmentCount": 6,
    "leadSponsor": "City of Hope Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Cancer Institute (NCI)"
    ],
    "conditions": [
      "Stage 3 Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: AutoCD6-CAR Treg cells"
    ],
    "briefSummary": "Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormone that is involved in the tight regulation of blood glucose levels. In T1D, the beta-cells are mistakenly destroyed by autoreactive T cells resulting in insulin deficiency and an inability to regulate blood glucose levels. The cause for such an autoimmune reaction to beta-cells is under active investigation. T regulatory cells (Tregs), are specialized immune cells that typically act to control your immune system. Tregs can be modified in the laboratory to recognize and deactivate T1D-causing cells. This process is done by inserting a piece of DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next) into the Tregs. A non-infectious virus called a lentivirus will carry the piece of DNA into the cells that were collected from a donor. Tregs are then grown to large numbers in the laboratory and stored for treatment of T1D. It is not known whether these Tregs cells will treat T1D.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "35 Years",
    "healthyVolunteers": false,
    "startDate": "2026-06-01",
    "completionDate": "2026-09-14",
    "primaryCompletionDate": "2026-09-14",
    "firstPostedDate": "2026-02-09",
    "lastUpdatePostedDate": "2026-05-13",
    "locations": [
      {
        "facility": "City of Hope Medical Center",
        "city": "Duarte",
        "state": "California",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07395050",
    "scrapedAt": "2026-05-14T17:51:04.321Z"
  },
  {
    "nctId": "NCT03457168",
    "briefTitle": "Treatment of Hypertension During Sleep",
    "officialTitle": "A Prospective, Randomized, Open-label Clinical Trial on the Effects of Intensive Versus Conventional Control of Ambulatory-determined Asleep Systolic Blood Pressure Mean on Cardiovascular, Metabolic, and Renal Disease Risks",
    "acronym": "THADEUS",
    "organization": "University of Vigo",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 5320,
    "leadSponsor": "University of Vigo",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Hypertension",
      "Hypertension, Systolic"
    ],
    "interventions": [
      "PROCEDURE: Treatment of elevated asleep SBP mean"
    ],
    "briefSummary": "On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have established lower values of 130/80 mmHg for clinic systolic BP (SBP)/diastolic BP (DBP) as new diagnostic thresholds for hypertension and therapeutic targets for treatment of all individuals aged ≥18 years regardless of age, sex, or concomitant complications including presence of diabetes, chronic kidney disease (CKD), or history of past CVD event. According to these guidelines, the new proposed ambulatory BP measurment (ABPM) thresholds for diagnosis of hypertension in adults are 130/80 and 110/65 mmHg for the awake and asleep SBP/DBP means, respectively. However, the ACC/AHA guidelines do not provide any scientific evidence documenting neither the equivalence between these ABPM thresholds and the 130/80 mmHg cut-off values for OBPM nor the potential improved CVD event-free survival time of the proposed more intensive control of ambulatory BP.\n\nResults derived from observational prospective studies consistently document that therapeutic BP targets in hypertensive individuals, i.e., persons at increased CVD risk, should be established in terms of proper control of asleep BP. To date, no prospective randomized study has ever before evaluated which should be the adequate therapeutic ABPM target for most effective reduction of CVD risk. Accordingly, the Tratamiento de Hipertensión Arterial Durante el Sueño study (THADEUS, i.e., Treatment of Hypertension During Sleep) has been designed to prospectively evaluate if \"intensive control\" of asleep SBP mean proposed by the new ACC/AHA guidelines (\\<110 mmHg) in more effective than the so far its \"conventional control\" (\\<120 mmHg) to reduce CVD morbidity and mortality in hypertensive individuals.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2019-02-01",
    "completionDate": "2032-12-31",
    "primaryCompletionDate": "2031-12-31",
    "firstPostedDate": "2018-03-07",
    "lastUpdatePostedDate": "2024-12-06",
    "locations": [
      {
        "facility": "Complexo Hospitalario Universitario de Ourense",
        "city": "Ourense",
        "state": "Orense",
        "country": "Spain"
      },
      {
        "facility": "CS A Estrada",
        "city": "A Estrada",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "CS Panxón",
        "city": "Nigrán",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "Centro de Salud de A Doblada",
        "city": "Vigo",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "Centro de Salud de Bembrive",
        "city": "Vigo",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "Centro de Salud de Sardoma",
        "city": "Vigo",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "CS Teis",
        "city": "Vigo",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "Bioengineering & Chronobilogy Labs., University of Vigo",
        "city": "Vigo",
        "state": "Pontevedra",
        "country": "Spain"
      },
      {
        "facility": "CS San Roque",
        "city": "Vilagarcía de Arousa",
        "state": "Pontevedra",
        "country": "Spain"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03457168",
    "scrapedAt": "2026-05-14T17:51:04.353Z"
  },
  {
    "nctId": "NCT06683391",
    "briefTitle": "Updating Preventive and Treatment Guidelines for Hypoglycemia in Individuals Living With Type 1 Diabetes",
    "officialTitle": "Updating pReventive and Treatment guidelinEs for Mild hypOglycemia in Individuals Living With Type 1 Diabetes During the erA of Continuous gLucose Monitoring: The REMODAL Trial",
    "acronym": "REMODAL",
    "organization": "Institut de Recherches Cliniques de Montreal",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 32,
    "leadSponsor": "Institut de Recherches Cliniques de Montreal",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "BEHAVIORAL: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment"
    ],
    "briefSummary": "The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \\< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2025-02-06",
    "completionDate": "2027-12-31",
    "primaryCompletionDate": "2026-12-31",
    "firstPostedDate": "2024-11-12",
    "lastUpdatePostedDate": "2025-02-25",
    "locations": [
      {
        "facility": "Institut de recherches cliniques de Montréal",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      },
      {
        "facility": "Montreal Clinical Research Institute",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06683391",
    "scrapedAt": "2026-05-14T17:51:04.389Z"
  },
  {
    "nctId": "NCT03915990",
    "briefTitle": "Middle Cerebral and Umbilical Arteries Doppler Indices in the Prediction of Adverse Neonatal Outcome Among Diabetic Pregnant Women",
    "officialTitle": "Middle Cerebral and Umbilical Arteries Doppler Indices in Pregestational Diabetic Versus Normal Pregnancies and Their Values in Predicting Adverse Neonatal Outcome",
    "acronym": null,
    "organization": "Cairo University",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 120,
    "leadSponsor": "Cairo University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "DIAGNOSTIC_TEST: umbilical and middle cerebral artery Doppler"
    ],
    "briefSummary": "120 patients will be included and divided into two groups; Control group that will include 60 healthy pregnant women and Study group that will include 60 pregestational diabetic pregnant patients which furtherly will be subdivided into two groups according to HbA1C levels namely; controlled diabetics ( will include 30 diabetic pregnant women with controlled DM - HbA1C \\< 6.5 %) and uncontrolled diabetics (will include 30 diabetic pregnant women with uncontrolled DM - HbA1C ≥ 6.5 %). Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient. The recorded neonatal outcomes will include neonatal birth weight, neonatal blood sugar, Apgar score at 1 \\& 5 min and neonatal intensive care unit admission.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "40 Years",
    "healthyVolunteers": false,
    "startDate": "2019-07-01",
    "completionDate": "2020-12",
    "primaryCompletionDate": "2020-12",
    "firstPostedDate": "2019-04-16",
    "lastUpdatePostedDate": "2020-11-10",
    "locations": [
      {
        "facility": "kasr elainy hospital (Faculty of Medicine - Cairo University)",
        "city": "Cairo",
        "state": null,
        "country": "Egypt"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03915990",
    "scrapedAt": "2026-05-14T17:51:04.424Z"
  },
  {
    "nctId": "NCT00476710",
    "briefTitle": "Effects of Colesevelam HCl On Bile Acid Kinetics",
    "officialTitle": "Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus",
    "acronym": null,
    "organization": "KineMed",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 36,
    "leadSponsor": "KineMed",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Daiichi Sankyo",
      "University Medical Center Groningen",
      "Diabetes & Glandular Disease Research Associates"
    ],
    "conditions": [
      "Type 2 Diabetes Mellitus",
      "Impaired Glucose Tolerance"
    ],
    "interventions": [
      "DRUG: Colesevelam HCl"
    ],
    "briefSummary": "This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.",
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "60 Years",
    "healthyVolunteers": true,
    "startDate": "2007-05",
    "completionDate": "2009-04",
    "primaryCompletionDate": "2009-04",
    "firstPostedDate": "2007-05-22",
    "lastUpdatePostedDate": "2015-04-01",
    "locations": [
      {
        "facility": "Diabetes & Glandular Disease Research Associates, Inc.",
        "city": "San Antonio",
        "state": "Texas",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00476710",
    "scrapedAt": "2026-05-14T17:51:04.462Z"
  },
  {
    "nctId": "NCT01659697",
    "briefTitle": "Diabetes Prevention in Prediabetic Patients",
    "officialTitle": "Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention",
    "acronym": "DPEP",
    "organization": "Meir Medical Center",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 200,
    "leadSponsor": "Meir Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Clalit Health Services"
    ],
    "conditions": [
      "Ethnic Group",
      "Young Adults",
      "Prediabetes",
      "Community Health Services"
    ],
    "interventions": [
      "BEHAVIORAL: intensive lifestyle counseling"
    ],
    "briefSummary": "This study will evaluate the feasibility and efficacy of two interventions of lifestyle ( intensive and less intensive) to prevent diabetes in patients from Ethiopian origin, aged 25 to 55 years old with prediabetes living in Israel and insured by Clalit Health Services in the Central district, using resources existing in this Health Care system (HMO).",
    "sex": "ALL",
    "minimumAge": "25 Years",
    "maximumAge": "55 Years",
    "healthyVolunteers": false,
    "startDate": "2012-08",
    "completionDate": "2015-07",
    "primaryCompletionDate": "2014-12",
    "firstPostedDate": "2012-08-08",
    "lastUpdatePostedDate": "2012-08-08",
    "locations": [
      {
        "facility": "Central district Clalit Health Services",
        "city": "Rishon LeZiyyon",
        "state": null,
        "country": "Israel"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01659697",
    "scrapedAt": "2026-05-14T17:51:04.605Z"
  },
  {
    "nctId": "NCT00974090",
    "briefTitle": "Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes",
    "officialTitle": "A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus",
    "acronym": null,
    "organization": "Tanabe Pharma Corporation",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 194,
    "leadSponsor": "Tanabe Pharma Corporation",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)",
      "DRUG: Teneli / Teneli + SU"
    ],
    "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": false,
    "startDate": "2009-09",
    "completionDate": "2011-03",
    "primaryCompletionDate": "2011-03",
    "firstPostedDate": "2009-09-10",
    "lastUpdatePostedDate": "2026-01-05",
    "locations": [
      {
        "facility": null,
        "city": "Sapporo",
        "state": "Hokkaido",
        "country": "Japan"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT00974090",
    "scrapedAt": "2026-05-14T17:51:04.688Z"
  },
  {
    "nctId": "NCT01583790",
    "briefTitle": "Factors Influencing the Positive Outcome of Bariatric Surgery for Morbidly Obese Patients",
    "officialTitle": "A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life",
    "acronym": null,
    "organization": "Assuta Hospital Systems",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 2000,
    "leadSponsor": "Assuta Hospital Systems",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Morbid Obesity",
      "Diabetes",
      "Hypertension"
    ],
    "interventions": [],
    "briefSummary": "The purpose of this study is to report data with patients after bariatric surgery.",
    "sex": "ALL",
    "minimumAge": "14 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2012-01",
    "completionDate": "2020-01",
    "primaryCompletionDate": "2019-01",
    "firstPostedDate": "2012-04-24",
    "lastUpdatePostedDate": "2018-01-25",
    "locations": [
      {
        "facility": "Assuta Medical Center",
        "city": "Tel Aviv",
        "state": null,
        "country": "Israel"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01583790",
    "scrapedAt": "2026-05-14T17:51:04.712Z"
  },
  {
    "nctId": "NCT00746460",
    "briefTitle": "The Healthy Options Feasibility Study",
    "officialTitle": "The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a \"Groupe de Médecine de Famille\": The Healthy Options Feasibility Study.",
    "acronym": null,
    "organization": "McGill University",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 50,
    "leadSponsor": "McGill University",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Pfizer"
    ],
    "conditions": [
      "Obesity",
      "Sedentary Lifestyle",
      "Dyslipidemia",
      "Hypertension",
      "Cigarette Smoking",
      "Diabetes"
    ],
    "interventions": [
      "BEHAVIORAL: CVD risk profile"
    ],
    "briefSummary": "The investigators hypothesize that having health care providers other than physicians within a \"Groupe de Médecine de Famille\" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention patients will increase the likelihood that patients will adopt and maintain healthy lifestyles. These objectives will be supported by providing subjects with a cardiovascular risk profile estimating the subject's risk of cardiovascular disease and teaching them how to use the resources related to lifestyle changes available on the www.myhealthcheckup.com Web site.",
    "sex": "ALL",
    "minimumAge": "30 Years",
    "maximumAge": "79 Years",
    "healthyVolunteers": false,
    "startDate": "2008-06",
    "completionDate": "2009-10",
    "primaryCompletionDate": "2009-04",
    "firstPostedDate": "2008-09-04",
    "lastUpdatePostedDate": "2014-01-14",
    "locations": [
      {
        "facility": "McGill Cardiovascular Health Improvement Program",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00746460",
    "scrapedAt": "2026-05-14T17:51:04.762Z"
  },
  {
    "nctId": "NCT05463744",
    "briefTitle": "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy",
    "officialTitle": "A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy",
    "acronym": "QWINT-5",
    "organization": "Eli Lilly and Company",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 692,
    "leadSponsor": "Eli Lilly and Company",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes",
      "Diabetes"
    ],
    "interventions": [
      "DRUG: Insulin Efsitora Alfa",
      "DRUG: Insulin Degludec"
    ],
    "briefSummary": "The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2022-08-12",
    "completionDate": "2024-05-07",
    "primaryCompletionDate": "2024-05-07",
    "firstPostedDate": "2022-07-19",
    "lastUpdatePostedDate": "2025-06-24",
    "locations": [
      {
        "facility": "John Muir Physician Network Research Center",
        "city": "Concord",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Valley Research",
        "city": "Fresno",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Catalina Research Institute, LLC",
        "city": "Montclair",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Sansum Diabetes Research Institute",
        "city": "Santa Barbara",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "University Clinical Investigators, Inc.",
        "city": "Tustin",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "University of Colorado Anschutz Medical Campus",
        "city": "Aurora",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "Northeast Research Institute (NERI)",
        "city": "Fleming Island",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care",
        "city": "Fort Lauderdale",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Suncoast Clinical Research, Inc.",
        "city": "New Port Richey",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Hanson Clinical Research Center",
        "city": "Port Charlotte",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "East Coast Institute for Research at The Jones Center",
        "city": "Macon",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "East-West Medical Research Institute",
        "city": "Honolulu",
        "state": "Hawaii",
        "country": "United States"
      },
      {
        "facility": "Rocky Mountain Clinical Research",
        "city": "Idaho Falls",
        "state": "Idaho",
        "country": "United States"
      },
      {
        "facility": "Iowa Diabetes and Endocrinology Research Center",
        "city": "West Des Moines",
        "state": "Iowa",
        "country": "United States"
      },
      {
        "facility": "Cotton O'Neil Clinical Research Center",
        "city": "Topeka",
        "state": "Kansas",
        "country": "United States"
      },
      {
        "facility": "MedStar Health Research Institute (MedStar Physician Based Research Network)",
        "city": "Hyattsville",
        "state": "Maryland",
        "country": "United States"
      },
      {
        "facility": "Endocrine and Metabolic Consultants",
        "city": "Rockville",
        "state": "Maryland",
        "country": "United States"
      },
      {
        "facility": "Clinvest Research LLC",
        "city": "Springfield",
        "state": "Missouri",
        "country": "United States"
      },
      {
        "facility": "Palm Research Center Tenaya",
        "city": "Las Vegas",
        "state": "Nevada",
        "country": "United States"
      },
      {
        "facility": "Palm Research Center Sunset",
        "city": "Las Vegas",
        "state": "Nevada",
        "country": "United States"
      },
      {
        "facility": "Research Foundation of SUNY - University of Buffalo",
        "city": "Buffalo",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "NYU Langone Hospital - Long Island",
        "city": "Mineola",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "NYC Research",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "SUNY Upstate Medical University",
        "city": "Syracuse",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "Thomas Jefferson University Hospital",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "Texas Diabetes & Endocrinology, P.A.",
        "city": "Austin",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Dallas Diabetes Research Center",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "North Texas Endocrine Center",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Research Institute of Dallas",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Biopharma Informatic, LLC",
        "city": "Houston",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Amir A Hassan, MD, PA",
        "city": "Houston",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Southern Endocrinology Associates",
        "city": "Mesquite",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Texas Diabetes & Endocrinology, P.A.",
        "city": "Round Rock",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Rainier Clinical Research Center",
        "city": "Renton",
        "state": "Washington",
        "country": "United States"
      },
      {
        "facility": "CEDIC",
        "city": "CABA",
        "state": "Buenos Aires",
        "country": "Argentina"
      },
      {
        "facility": "Centro de Investigaciones Metabólicas (CINME)",
        "city": "Ciudad Autónoma de Buenos Aire",
        "state": "Buenos Aires",
        "country": "Argentina"
      },
      {
        "facility": "Consultorio de Investigación Clínica EMO SRL",
        "city": "Ciudad Autonoma de Buenos Aire",
        "state": "Buenos Air",
        "country": "Argentina"
      },
      {
        "facility": "CIAD Moron",
        "city": "Morón",
        "state": "Buenos Air",
        "country": "Argentina"
      },
      {
        "facility": "Investigaciones Medicas Imoba Srl",
        "city": "Balvanera",
        "state": "Ciudad Autónoma de Buenos Aire",
        "country": "Argentina"
      },
      {
        "facility": "Mautalen Salud e Investigación",
        "city": "Buenos Aires",
        "state": "Ciudad Autónoma de Buenos Aire",
        "country": "Argentina"
      },
      {
        "facility": "Centro Medico Privado CEMAIC",
        "city": "Capital",
        "state": "Córdoba Province",
        "country": "Argentina"
      },
      {
        "facility": "Centro Medico Privado San Vicente Diabetes",
        "city": "Córdoba",
        "state": "Córdoba Province",
        "country": "Argentina"
      },
      {
        "facility": "Centro de Salud e Investigaciones Médicas",
        "city": "Santa Rosa",
        "state": "La Pampa Province",
        "country": "Argentina"
      },
      {
        "facility": "CIPADI - Centro Integral de Prevencion y Atencion en Diabetes",
        "city": "Godoy Cruz",
        "state": "Mendoza Province",
        "country": "Argentina"
      },
      {
        "facility": "Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L",
        "city": "San Miguel de Tucumán",
        "state": "Tucumán Province",
        "country": "Argentina"
      },
      {
        "facility": "Centro Medico Privado de Reumatologia",
        "city": "San Miguel de Tucumán",
        "state": "Tucumán Province",
        "country": "Argentina"
      },
      {
        "facility": "Instituto Médico Especializado (IME)",
        "city": "Buenos Aires",
        "state": null,
        "country": "Argentina"
      },
      {
        "facility": "Centro Diabetológico Dr. Waitman",
        "city": "Córdoba",
        "state": null,
        "country": "Argentina"
      },
      {
        "facility": "Tosaki Clinic for Diabetes and Endocrinology",
        "city": "Nagoya",
        "state": "Aichi-ken",
        "country": "Japan"
      },
      {
        "facility": "Manda Memorial Hospital",
        "city": "Sapporo",
        "state": "Hokkaido",
        "country": "Japan"
      },
      {
        "facility": "MinamiAkatsukaClinic",
        "city": "Mito",
        "state": "Ibaraki",
        "country": "Japan"
      },
      {
        "facility": "Nakakinen clinic",
        "city": "Naka",
        "state": "Ibaraki",
        "country": "Japan"
      },
      {
        "facility": "Noritake Clinic",
        "city": "Ushiku",
        "state": "Ibaraki",
        "country": "Japan"
      },
      {
        "facility": "Takai Internal Medicine Clinic",
        "city": "Kamakura-shi",
        "state": "Kanagawa",
        "country": "Japan"
      },
      {
        "facility": "Takatsuki Red Cross Hospital",
        "city": "Takatsuki",
        "state": "Osaka",
        "country": "Japan"
      },
      {
        "facility": "Shimizu Clinic Fusa",
        "city": "Saitama-shi",
        "state": "Saitama",
        "country": "Japan"
      },
      {
        "facility": "The Institute for Adult Disease, Asahi Life Foundation",
        "city": "Chuo-ku",
        "state": "Tokyo",
        "country": "Japan"
      },
      {
        "facility": "Hachioji Diabetes Clinic",
        "city": "Hachioji-shi",
        "state": "Tokyo",
        "country": "Japan"
      },
      {
        "facility": "Clinic Masae Minami",
        "city": "Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Jinnouchi Hospital",
        "city": "Kumamoto",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Heiwadai Hospital",
        "city": "Miyazaki",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Abe Clinic",
        "city": "Ōita",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET",
        "city": "Krakow",
        "state": "Lesser Poland Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Gabinety TERPA",
        "city": "Lublin",
        "state": "Lublin Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "NZOZ Medica",
        "city": "Lublin",
        "state": "Lublin Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Centrum Medyczne \"Diabetika\"",
        "city": "Radom",
        "state": "Masovian Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Centralny Szpital Kliniczny MSWiA w Warszawie",
        "city": "Warsaw",
        "state": "Masovian Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "NBR Polska",
        "city": "Warsaw",
        "state": "Mazowiecki",
        "country": "Poland"
      },
      {
        "facility": "SN ZOZ Lege Artis Poradnia Diabetologiczna",
        "city": "Bialystok",
        "state": "Podlaskie Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny",
        "city": "Bialystok",
        "state": "Podlaskie Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Centrum Badan Klinicznych PI-House sp. z o.o.",
        "city": "Gdansk",
        "state": "Pomeranian Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Private Practice - Dr. Janusz Gumprecht",
        "city": "Zabrze",
        "state": "Silesian Voivodeship",
        "country": "Poland"
      },
      {
        "facility": "Advanced Clinical Research, LLC",
        "city": "Bayamón",
        "state": null,
        "country": "Puerto Rico"
      },
      {
        "facility": "Endocrinologist Metabolic Clinic & Research Institute",
        "city": "San Juan",
        "state": null,
        "country": "Puerto Rico"
      },
      {
        "facility": "Tatratrial s.r.o.",
        "city": "Rožňava",
        "state": "Košice Region",
        "country": "Slovakia"
      },
      {
        "facility": "Funkystuff",
        "city": "Nové Zámky",
        "state": "Nitra Region",
        "country": "Slovakia"
      },
      {
        "facility": "ENDIAMED s.r.o",
        "city": "Dolný Kubín",
        "state": "Žilina Region",
        "country": "Slovakia"
      },
      {
        "facility": "Chung Shan Medical University Hospital",
        "city": "Taichung",
        "state": "Taichung",
        "country": "Taiwan"
      },
      {
        "facility": "Taichung Veterans General Hospital",
        "city": "Taichung",
        "state": "Taichung",
        "country": "Taiwan"
      },
      {
        "facility": "Chi Mei Medical Center",
        "city": "Tainan",
        "state": "Tainan",
        "country": "Taiwan"
      },
      {
        "facility": "Taipei Veterans General Hospital",
        "city": "Taipei City",
        "state": "Taipei",
        "country": "Taiwan"
      },
      {
        "facility": "Changhua Christian Hospital",
        "city": "Changhua",
        "state": null,
        "country": "Taiwan"
      },
      {
        "facility": "National Cheng Kung University Hospital",
        "city": "Tainan",
        "state": null,
        "country": "Taiwan"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT05463744",
    "scrapedAt": "2026-05-14T17:51:04.834Z"
  },
  {
    "nctId": "NCT03331432",
    "briefTitle": "Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function",
    "officialTitle": "Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation",
    "acronym": null,
    "organization": "University of Missouri-Columbia",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 8,
    "leadSponsor": "University of Missouri-Columbia",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Tauroursodeoxycholic acid",
      "DIETARY_SUPPLEMENT: Placebo"
    ],
    "briefSummary": "The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2015-10-28",
    "completionDate": "2018-02-14",
    "primaryCompletionDate": "2017-08-15",
    "firstPostedDate": "2017-11-06",
    "lastUpdatePostedDate": "2018-02-19",
    "locations": [
      {
        "facility": "University of Missouri",
        "city": "Columbia",
        "state": "Missouri",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03331432",
    "scrapedAt": "2026-05-14T17:51:04.875Z"
  },
  {
    "nctId": "NCT05785832",
    "briefTitle": "A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes",
    "officialTitle": "A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)",
    "acronym": "2IQP",
    "organization": "Tandem Diabetes Care, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 319,
    "leadSponsor": "Tandem Diabetes Care, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Jaeb Center for Health Research"
    ],
    "conditions": [
      "Type 2 Diabetes Treated With Insulin"
    ],
    "interventions": [
      "DEVICE: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM",
      "DEVICE: Standard Therapy plus continuous glucose monitoring (CGM)"
    ],
    "briefSummary": "A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2023-06-01",
    "completionDate": "2024-09-24",
    "primaryCompletionDate": "2024-09-24",
    "firstPostedDate": "2023-03-27",
    "lastUpdatePostedDate": "2026-02-19",
    "locations": [
      {
        "facility": "Hoag Memorial Hospital Presbyterian",
        "city": "Newport Beach",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Emory University School of Medicine",
        "city": "Atlanta",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "Rocky Mountain Clinical Research",
        "city": "Idaho Falls",
        "state": "Idaho",
        "country": "United States"
      },
      {
        "facility": "Northwestern University",
        "city": "Chicago",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "Baltimore VA Medical Center",
        "city": "Baltimore",
        "state": "Maryland",
        "country": "United States"
      },
      {
        "facility": "Boston Medical Center Corporation",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "Henry Ford Health System",
        "city": "Detroit",
        "state": "Michigan",
        "country": "United States"
      },
      {
        "facility": "Mayo Clinic",
        "city": "Rochester",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Icahn School of Medicine at Mt. Sinai",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "SUNY Upstate Medical University",
        "city": "Syracuse",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "UHH Cleveland Medical Center",
        "city": "Cleveland",
        "state": "Ohio",
        "country": "United States"
      },
      {
        "facility": "Oregon Health & Science University",
        "city": "Portland",
        "state": "Oregon",
        "country": "United States"
      },
      {
        "facility": "University of Pennsylvania",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "Texas Diabetes and Endocrinology, P.A.",
        "city": "Austin",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "University of Texas Southwestern",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Diabetes & Endocrine Treatment Specialists",
        "city": "Sandy City",
        "state": "Utah",
        "country": "United States"
      },
      {
        "facility": "University of Virginia",
        "city": "Charlottesville",
        "state": "Virginia",
        "country": "United States"
      },
      {
        "facility": "Rainier Clinical Research Center",
        "city": "Renton",
        "state": "Washington",
        "country": "United States"
      },
      {
        "facility": "University of Washington",
        "city": "Seattle",
        "state": "Washington",
        "country": "United States"
      },
      {
        "facility": "Lawson Health Research Institute",
        "city": "London",
        "state": "Ontario",
        "country": "Canada"
      },
      {
        "facility": "McGill University",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT05785832",
    "scrapedAt": "2026-05-14T17:51:04.914Z"
  },
  {
    "nctId": "NCT03314714",
    "briefTitle": "Duality of Lipids: the Athlete's Paradox",
    "officialTitle": "The Dual Role of Intramyocellular Lipids in Mediating Insulin Resistance: Assessing the Mechanisms of the Athlete's Paradox",
    "acronym": "LIDDIA",
    "organization": "German Diabetes Center",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 100,
    "leadSponsor": "German Diabetes Center",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Maastricht University"
    ],
    "conditions": [
      "Insulin Resistance, Diabetes",
      "Lipid Metabolism Disorders"
    ],
    "interventions": [
      "PROCEDURE: Acute bout of endurance exercise"
    ],
    "briefSummary": "Accumulation of intramyocellular lipids (IMCLs) due to increased supply of fatty acids can induce defects in the insulin signaling cascade, causing skeletal muscle insulin resistance. However, the causes for muscle insulin resistance are not well understood. The association of elevated IMCLs and insulin resistance has been shown in obese humans and individuals with type 2 diabetes as well as several animal models of insulin resistance. Despite the strong relationship between IMCLs and insulin resistance, this suggested relationship disappears when well-trained endurance athletes are included into this consideration as this group is highly insulin sensitive. This metabolic enigma has been termed the 'athlete's paradox'. The aim of this project is to resolve the mechanisms contributing to the athlete's paradox.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "69 Years",
    "healthyVolunteers": true,
    "startDate": "2017-04-03",
    "completionDate": "2023-06-01",
    "primaryCompletionDate": "2023-06-01",
    "firstPostedDate": "2017-10-19",
    "lastUpdatePostedDate": "2023-06-13",
    "locations": [
      {
        "facility": "German Diabetes Center",
        "city": "Düsseldorf",
        "state": "North Rhine-Westphalia",
        "country": "Germany"
      },
      {
        "facility": "Maastricht University",
        "city": "Maastricht",
        "state": null,
        "country": "Netherlands"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03314714",
    "scrapedAt": "2026-05-14T17:51:04.940Z"
  },
  {
    "nctId": "NCT06760416",
    "briefTitle": "Online Diabetic Foot Support Program- Care Kit",
    "officialTitle": "Effect of Online Diabetic Foot Support Program (DiaFootSuP) and Care Kit on Diabetic Foot Care Outcomes: Randomized Controlled Trial",
    "acronym": "DiaFootSuP",
    "organization": "Dokuz Eylul University",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 62,
    "leadSponsor": "Merve GÃnbaAY",
    "sponsorClass": "OTHER",
    "collaborators": [
      "The Scientific and Technological Research Council of Turkey"
    ],
    "conditions": [
      "Diabetes Mellitus",
      "Diabetic Foot Ulcer",
      "Diabetic Foot"
    ],
    "interventions": [
      "OTHER: Nursing Education"
    ],
    "briefSummary": "The aim of this project is to examine the effects of the online diabetic foot support program (DiaFootSuP) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, HbA1c, etc.).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2024-11-01",
    "completionDate": "2025-03-31",
    "primaryCompletionDate": "2024-12-27",
    "firstPostedDate": "2025-01-06",
    "lastUpdatePostedDate": "2025-01-06",
    "locations": [
      {
        "facility": "Dokuz Eylül University",
        "city": "Izmir",
        "state": "Buca",
        "country": "Turkey (Türkiye)"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06760416",
    "scrapedAt": "2026-05-14T17:51:04.983Z"
  },
  {
    "nctId": "NCT04024306",
    "briefTitle": "Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients",
    "officialTitle": "Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients",
    "acronym": null,
    "organization": "Assiut University",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 120,
    "leadSponsor": "Assiut University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "System; Lupus Erythematosus"
    ],
    "interventions": [],
    "briefSummary": "The aim of the study is to determine the prevalence of steroid-induced diabetes mellitus (SDM) among systemic lupus erythematosus (SLE) patients and identify and assess the associated risk factors .",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": false,
    "startDate": "2022-09-01",
    "completionDate": "2024-04-20",
    "primaryCompletionDate": "2024-04-01",
    "firstPostedDate": "2019-07-18",
    "lastUpdatePostedDate": "2023-07-19",
    "locations": [
      {
        "facility": "Assiut university hospital",
        "city": "Asyut",
        "state": null,
        "country": "Egypt"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04024306",
    "scrapedAt": "2026-05-14T17:51:04.999Z"
  },
  {
    "nctId": "NCT00607906",
    "briefTitle": "First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050",
    "officialTitle": "A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus",
    "acronym": null,
    "organization": "GlaxoSmithKline",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 36,
    "leadSponsor": "GlaxoSmithKline",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: SB-756050 immediate release capsule",
      "DRUG: SB-756050 modified release capsule",
      "DRUG: Placebo"
    ],
    "briefSummary": "This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "60 Years",
    "healthyVolunteers": true,
    "startDate": "2007-11-16",
    "completionDate": "2008-03-10",
    "primaryCompletionDate": "2008-03-10",
    "firstPostedDate": "2008-02-06",
    "lastUpdatePostedDate": "2017-09-06",
    "locations": [
      {
        "facility": "GSK Investigational Site",
        "city": "Minneapolis",
        "state": "Minnesota",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00607906",
    "scrapedAt": "2026-05-14T17:51:05.053Z"
  },
  {
    "nctId": "NCT05251506",
    "briefTitle": "The Evaluation of Laser Lancing Devices in Adult Type 2 Diabetes Patients",
    "officialTitle": "The Evaluation of Laser Lancing Devices in Constructing Self-management Systems for Chronic Diseases in Adult Diabetes Patients",
    "acronym": null,
    "organization": "Korea University Guro Hospital",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 80,
    "leadSponsor": "Korea University Guro Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Korea Medical Device Development Fund"
    ],
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "DEVICE: laser lancing device or lancet for blood glucose level measurement"
    ],
    "briefSummary": "Self monitoring of blood glucose level is crucial in diabetes management, but currently available methods, lancet, have shown low compliance of self monitoring of blood glucose because of pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.\n\nThe investigators recruit total of 80 type 2 diabetes patients who visit Korea University Medical center Guro and Ansan hospital. HbA1c level of subject is more than 6.5% and less than 8.5%, and their age is above 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B perform the process vice versa. The investigators evaluate the number of blood glucose measurement, HbA1c, diabetes distress scale, average pain score, average satisfaction score from each group.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "79 Years",
    "healthyVolunteers": false,
    "startDate": "2021-08-10",
    "completionDate": "2022-12-31",
    "primaryCompletionDate": "2022-03-31",
    "firstPostedDate": "2022-02-22",
    "lastUpdatePostedDate": "2022-02-22",
    "locations": [
      {
        "facility": "Korea University medical center",
        "city": "Seoul",
        "state": null,
        "country": "South Korea"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05251506",
    "scrapedAt": "2026-05-14T17:51:05.121Z"
  },
  {
    "nctId": "NCT02898506",
    "briefTitle": "Incretin-based Therapy in Late Preclinical Type 1 Diabetes",
    "officialTitle": "Incretin-based Therapy in Late Preclinical Type 1 Diabetes",
    "acronym": null,
    "organization": "University of Oulu",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 13,
    "leadSponsor": "University of Oulu",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Oulu University Hospital",
      "Tampere University Hospital",
      "Turku University Hospital",
      "Skane University Hospital"
    ],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: Victoza®",
      "DRUG: Placebo"
    ],
    "briefSummary": "The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.",
    "sex": "ALL",
    "minimumAge": "10 Years",
    "maximumAge": "30 Years",
    "healthyVolunteers": false,
    "startDate": "2016-03",
    "completionDate": "2021-06",
    "primaryCompletionDate": "2021-06",
    "firstPostedDate": "2016-09-13",
    "lastUpdatePostedDate": "2022-01-25",
    "locations": [
      {
        "facility": "University of Oulu and Oulu University Hospital, Dept of Children and Adolescents",
        "city": "Oulu",
        "state": null,
        "country": "Finland"
      },
      {
        "facility": "University of Tampere and Tampere University Hospital",
        "city": "Tampere",
        "state": null,
        "country": "Finland"
      },
      {
        "facility": "University of Turku and Turku University Hospital",
        "city": "Turku",
        "state": null,
        "country": "Finland"
      },
      {
        "facility": "Lund University and Skåne University Hospital",
        "city": "Malmö",
        "state": null,
        "country": "Sweden"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02898506",
    "scrapedAt": "2026-05-14T17:51:05.147Z"
  },
  {
    "nctId": "NCT04361552",
    "briefTitle": "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",
    "officialTitle": "Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial",
    "acronym": null,
    "organization": "Emory University",
    "overallStatus": "WITHDRAWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 0,
    "leadSponsor": "Emory University",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Cancer Institute (NCI)"
    ],
    "conditions": [
      "Cerebrovascular Accident",
      "Chronic Obstructive Pulmonary Disease",
      "Chronic Renal Failure",
      "Coronary Artery Disease",
      "Diabetes Mellitus",
      "Malignant Neoplasm",
      "SARS Coronavirus 2 Infection"
    ],
    "interventions": [
      "OTHER: Best Practice",
      "BIOLOGICAL: Tocilizumab"
    ],
    "briefSummary": "This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2020-04-07",
    "completionDate": "2020-06-02",
    "primaryCompletionDate": "2020-06-02",
    "firstPostedDate": "2020-04-24",
    "lastUpdatePostedDate": "2020-06-18",
    "locations": [
      {
        "facility": "Emory University Hospital/Winship Cancer Institute",
        "city": "Atlanta",
        "state": "Georgia",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04361552",
    "scrapedAt": "2026-05-14T17:51:05.194Z"
  },
  {
    "nctId": "NCT05184049",
    "briefTitle": "Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients",
    "officialTitle": "Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient",
    "acronym": null,
    "organization": "Xiangya Hospital of Central South University",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 72,
    "leadSponsor": "Xiangya Hospital of Central South University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes"
    ],
    "interventions": [
      "DRUG: Epalrestat,Mecobalamin",
      "DRUG: Mecobalamin"
    ],
    "briefSummary": "This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2022-01",
    "completionDate": "2023-10",
    "primaryCompletionDate": "2023-10",
    "firstPostedDate": "2022-01-11",
    "lastUpdatePostedDate": "2022-01-11",
    "locations": [
      {
        "facility": "Xiangya Hospital of Central South University",
        "city": "Changsha",
        "state": "Hunan",
        "country": "China"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05184049",
    "scrapedAt": "2026-05-14T17:51:05.210Z"
  },
  {
    "nctId": "NCT00806338",
    "briefTitle": "An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers",
    "officialTitle": "A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers",
    "acronym": null,
    "organization": "Genaera Corporation",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 22,
    "leadSponsor": "Genaera Corporation",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus",
      "Obesity"
    ],
    "interventions": [
      "DRUG: Trodusquemine (MSI-1436)",
      "DRUG: Placebo"
    ],
    "briefSummary": "The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2008-11",
    "completionDate": "2009-04",
    "primaryCompletionDate": "2009-04",
    "firstPostedDate": "2008-12-10",
    "lastUpdatePostedDate": "2009-04-15",
    "locations": [
      {
        "facility": "Cetero Research",
        "city": "Miami Gardens",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "dgd Research",
        "city": "San Antonio",
        "state": "Texas",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00806338",
    "scrapedAt": "2026-05-14T17:51:05.234Z"
  },
  {
    "nctId": "NCT07258758",
    "briefTitle": "Diabetes Intervention Involving Person-centred Nutritional Education",
    "officialTitle": "Diabetes Intervention Involving Person-centred Nutritional Education (DINE) - Exploring the Benefits and Challenges of a Person-centred Education on the Nordic Diet for Adults With Type 1 Diabetes.",
    "acronym": "DINE",
    "organization": "Umeå University",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 54,
    "leadSponsor": "Umeå University",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Lasarettet i Enköping"
    ],
    "conditions": [
      "Diabetes Type 1"
    ],
    "interventions": [
      "BEHAVIORAL: Dietary intervention"
    ],
    "briefSummary": "The overall objective for this project is to evaluate the effects of a person-centred education intervention to promote a healthy, sustainable Nordic diet compared with the current practice of providing short dietary information on health outcomes of adults with Type 1 diabetes. The study will measure the intervention's impact on blood glucose levels, blood lipids, blood pressure, and adherence to a sustainable and healthy Nordic diet.\n\nThe main question the trial aims to answer is:\n\nDoes a person-centred nutritional education have an impact on glucose time in range for adults with Type 1 diabetes, compared with short dietary information?\n\nThe participants will:\n\n* Attend either a person-centred nutrition education (intervention) or receive short dietary information (control group).\n* Wear their sensor for continuous glucose monitoring (CGM) throughout the trial.\n* Visit the clinic for data collection (blood samples and clinical checks) at the start and end of the trial.\n* Keep a four-day food diary, fill out a food frequency questionnaire (FFQ) and estimate their food enjoyment at the start and end of the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2025-09-01",
    "completionDate": "2027-06",
    "primaryCompletionDate": "2027-06",
    "firstPostedDate": "2025-12-02",
    "lastUpdatePostedDate": "2025-12-12",
    "locations": [
      {
        "facility": "Hospital of Enköping",
        "city": "Enköping",
        "state": "Uppland",
        "country": "Sweden"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07258758",
    "scrapedAt": "2026-05-14T17:51:05.277Z"
  },
  {
    "nctId": "NCT03574558",
    "briefTitle": "Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study",
    "officialTitle": "Personalized Automated Determination of Insulin Pump Setting for Subjects With Type 1 Diabetes Switching From MDI to Pump Therapy and Vice Versa- Safety and Efficacy Feasibility Study",
    "acronym": null,
    "organization": "Rabin Medical Center",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 28,
    "leadSponsor": "Rabin Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Juvenile Diabetes Research Foundation",
      "Jaeb Center for Health Research",
      "DreaMed",
      "University of Padova"
    ],
    "conditions": [
      "Type1diabetes"
    ],
    "interventions": [
      "DEVICE: MD-Logic Switch Advisor"
    ],
    "briefSummary": "The \"MD-Logic Switch Advisor\" is a software product that is designed to assist in insulin dosage decision making and has two components:\n\nA. MD-Logic Switch Advisor for initiation of pump therapy - this product is designed to assist physicians in decision making when initiating insulin pump therapy.\n\nB. MD-Logic Switch Advisor for patients who use insulin pump therapy and need to switch to MDI (Multiple Daily Injections).\n\nThis feasibility study will be divided to two parts:\n\npart A - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from MDI to pump therapy part B - will include up to 20 patients to evaluate in a feasibility study the switch Advisor from pump therapy to MDI The main objective is to evaluate the safety and efficacy of using the MD-Logic Switch Advisor to determine insulin dosing for subjects with type 1 diabetes using pump therapy who wish to switch to from pump to MDI therapy and vice versa.",
    "sex": "ALL",
    "minimumAge": "6 Years",
    "maximumAge": "30 Years",
    "healthyVolunteers": false,
    "startDate": "2018-08-01",
    "completionDate": "2019-11-25",
    "primaryCompletionDate": "2019-11-25",
    "firstPostedDate": "2018-07-02",
    "lastUpdatePostedDate": "2019-12-27",
    "locations": [
      {
        "facility": "Schnider children's medical center",
        "city": "Petah Tikva",
        "state": null,
        "country": "Israel"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03574558",
    "scrapedAt": "2026-05-14T17:51:05.316Z"
  },
  {
    "nctId": "NCT00516958",
    "briefTitle": "Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections",
    "officialTitle": "An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections",
    "acronym": null,
    "organization": "Oculus Innovative Sciences, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 65,
    "leadSponsor": "Oculus Innovative Sciences, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Foot Ulcer, Diabetic"
    ],
    "interventions": [
      "DRUG: Topical Dermacyn",
      "DRUG: Topical Dermacyn and Levofloxacin",
      "DRUG: Topical Saline and Levofloxacin"
    ],
    "briefSummary": "To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2007-05",
    "completionDate": "2007-12",
    "primaryCompletionDate": "2007-12",
    "firstPostedDate": "2007-08-16",
    "lastUpdatePostedDate": "2008-01-14",
    "locations": [
      {
        "facility": null,
        "city": "Tucson",
        "state": "Arizona",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "La Jolla",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Los Angeles",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "San Diego",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Santa Rosa",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Denver",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "New Haven",
        "state": "Connecticut",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Boca Raton",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Spring Hill",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Evansville",
        "state": "Indiana",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Louisville",
        "state": "Kentucky",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Harrisburgh",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Hazleton",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Pittsburgh",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": null,
        "city": "Salt Lake City",
        "state": "Utah",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00516958",
    "scrapedAt": "2026-05-14T17:51:05.347Z"
  },
  {
    "nctId": "NCT03510078",
    "briefTitle": "Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients",
    "officialTitle": "Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients",
    "acronym": null,
    "organization": "Rabin Medical Center",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 600,
    "leadSponsor": "Rabin Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus",
      "Non-critically Ill Patients"
    ],
    "interventions": [
      "DRUG: Insulin"
    ],
    "briefSummary": "Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe hyperglycemia is associated with increased morbidity and mortality in several populations. Several trials assessed the benefits of aggressive versus conventional glucose control. These studies evaluated different patient populations, glucose targets and treatment protocols and as a result reported conflicting results. To date there are no clear guidelines regarding to the preferred glucose target range in hospitalized non-critically ill patients. The common practice is to maintain glucose level lower than 180 mg/dl however there are no evidence based regarding to the outcomes of hospitalized patients treated with intensive compared to conventional glycemic control. This prospective randomized controlled study will compare intensive vs. standard glycemic control in hospitalized non-critically ill patients.\n\nWithin 24 hours of hospitalization in the internal medical or geriatric departments, patients who are expected to require hospitalization for at least three consecutive days will be randomly assigned into one of the two study groups - intensive with a target blood glucose range of 130 mg per deciliter or less, or conventional glucose control, with a target of 130-180 mg per deciliter. The investigators defined the primary end point as a composite outcome of mortality in 30 days, severe hypoglycemia, severe infections within 30 days, CVA and cardiac ischemic events within 30 days.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "120 Years",
    "healthyVolunteers": false,
    "startDate": "2018-04-17",
    "completionDate": "2025-12-10",
    "primaryCompletionDate": "2025-07-01",
    "firstPostedDate": "2018-04-27",
    "lastUpdatePostedDate": "2026-04-30",
    "locations": [
      {
        "facility": "Rabin Medical Center",
        "city": "Petah Tikva",
        "state": "Israel",
        "country": "Israel"
      },
      {
        "facility": "Soroka University Medical Center",
        "city": "Beersheba",
        "state": null,
        "country": "Israel"
      },
      {
        "facility": "Rambam Medical Center",
        "city": "Haifa",
        "state": null,
        "country": "Israel"
      },
      {
        "facility": "Shamir Medical Center",
        "city": "Ẕerifin",
        "state": null,
        "country": "Israel"
      },
      {
        "facility": "Unit of Geriatric Medicine University of Modena and Reggio Emilia, University Hospital of Baggiovara",
        "city": "Modena",
        "state": null,
        "country": "Italy"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03510078",
    "scrapedAt": "2026-05-14T17:51:05.400Z"
  },
  {
    "nctId": "NCT01293578",
    "briefTitle": "Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication",
    "officialTitle": "Translating Information on Comparative Effectiveness Into Practice (TRICEP)",
    "acronym": "TRICEP",
    "organization": "Mayo Clinic",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 550,
    "leadSponsor": "Mayo Clinic",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "OTHER: Diabetes Medication Choice Cards"
    ],
    "briefSummary": "The goal of this study is to test the relative merits of a decision aid for diabetes medications that we have developed - Diabetes Medication Choice Cards- versus usual care in translating comparative effectiveness research (CER) into real world clinics. This study will involve about 20 primary care practice sites affiliated with Mayo Health System, Park Nicollet, or Hennepin County Medical Center. There will be no recruiting done at the Mayo Clinic.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": true,
    "startDate": "2011-01",
    "completionDate": "2015-06",
    "primaryCompletionDate": "2015-06",
    "firstPostedDate": "2011-02-10",
    "lastUpdatePostedDate": "2022-09-28",
    "locations": [
      {
        "facility": "Albert Lea Medical Center",
        "city": "Albert Lea",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Mayo Clinic Kasson",
        "city": "Kasson",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Mayo Clinic Health System- Immanual St. Joseph's",
        "city": "Mankato",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Hennepin County Medical Center",
        "city": "Minneapolis",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Park Nicollet Institute",
        "city": "Saint Louis Park",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Mayo Clinic Health System-Franciscan Healthcare",
        "city": "La Crosse",
        "state": "Wisconsin",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01293578",
    "scrapedAt": "2026-05-14T17:51:05.417Z"
  },
  {
    "nctId": "NCT05659043",
    "briefTitle": "Glycation of apoA-I and Diabetic Atherogenesis",
    "officialTitle": "The Impact of Glycation Modification of apoA-I on HDL Function and Atherogenesis in Type Diabetes Mellitus",
    "acronym": null,
    "organization": "Ruijin Hospital",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 2000,
    "leadSponsor": "Ruijin Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "OTHER: overnight fasting"
    ],
    "briefSummary": "The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis.\n\nApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the development of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, by consecutively enrolling diabetic patients with (two to three hundred) or without CAD (controls, six to eight hundred) in our hospital, we will isolate their serum HDL and perform a qualitative and quantitative proteomic analysis of apoA-I glycation. The relation of apoA-I glycation and HDL function and angiography-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients to analyze the influence of apoA-I glycation on the outcome including plaque progression.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "90 Years",
    "healthyVolunteers": false,
    "startDate": "2017-01",
    "completionDate": "2023-12",
    "primaryCompletionDate": "2021-12",
    "firstPostedDate": "2022-12-21",
    "lastUpdatePostedDate": "2022-12-21",
    "locations": [
      {
        "facility": "Ruijin Hospital, Shanghai Jiaotong University School of Medicine",
        "city": "Shanghai",
        "state": "Shanghai Municipality",
        "country": "China"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05659043",
    "scrapedAt": "2026-05-14T17:51:05.501Z"
  },
  {
    "nctId": "NCT05767255",
    "briefTitle": "Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue",
    "officialTitle": "Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue",
    "acronym": null,
    "organization": "Hospital Universitario San Ignacio",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 66,
    "leadSponsor": "Hospital Universitario San Ignacio",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2 Treated With Insulin"
    ],
    "interventions": [
      "DRUG: insulin degludec + liraglutide",
      "DRUG: Insulin Glargine - Insulin Aspart"
    ],
    "briefSummary": "The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.\n\nThe DUAL (Dual Action of Liraglutide and Insulin Degludec) studies are the pivotal studies of this combination. Specifically, the DUAL VII study has demonstrated that ideglira is a non-inferior drug in terms of glycemic control versus a basal-bolus schedule in patients in the outpatient setting who have failed basal insulin.\n\nAlthough the basal-bolus insulin plus correction schedule is frequently used in hospitalized patients with hyperglycemia, outpatient management with a complex insulin schedule creates challenges that are difficult to mitigate due to limited time for patient education during an acute illness and limited access to the physician responsible for post-discharge diabetes management.\n\nThe use of IDegLira has not been evaluated in clinical studies in the hospital discharge setting where the authors believe it has great potential because it offers similar potency to the basal-bolus scheme but with greater safety with respect to hypoglycemia and less complexity for the patient because it is associated with fewer applications and less need for capillary self-monitoring.\n\nFor this reason, in the hospital-home transition scenario, ideglira therapy in patients with poor metabolic control and requiring intensification therapy is proposed as an alternative to the basal-bolus scheme.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2022-12-01",
    "completionDate": "2023-08-30",
    "primaryCompletionDate": "2023-08-30",
    "firstPostedDate": "2023-03-14",
    "lastUpdatePostedDate": "2023-03-14",
    "locations": [
      {
        "facility": "Hospital Universitario San Ignacio",
        "city": "Bogotá",
        "state": null,
        "country": "Colombia"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05767255",
    "scrapedAt": "2026-05-14T17:51:05.540Z"
  },
  {
    "nctId": "NCT05959135",
    "briefTitle": "Gastric Ultrasound in Diabetic and Non-Diabetic Pregnant Women",
    "officialTitle": "Ultrasound Evaluation of Gastric Content in Diabetic and Non-Diabetic Term Pregnant Women: An Observational Study",
    "acronym": null,
    "organization": "Sisli Hamidiye Etfal Training and Research Hospital",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 80,
    "leadSponsor": "Sisli Hamidiye Etfal Training and Research Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Gastric Ultrasonography",
      "Gastric Volume",
      "Pulmonary Aspiration",
      "Diabetic Pregnancy",
      "Fasting"
    ],
    "interventions": [
      "DEVICE: Gastric ultrasonography"
    ],
    "briefSummary": "Perioperative aspiration is particularly concerning in pregnant women due to anatomical changes. To mitigate this risk, pre-anesthetic fasting is recommended, with varying guidelines. Gastric ultrasound can non-invasively assess stomach contents, and mathematical models help estimate stomach volumes using the gastric antral cross-sectional area (CSA).\n\nThis study aims to compare CSA and estimated gastric volumes through ultrasound in fasting diabetic and non-diabetic pregnant women scheduled for cesarean section, as diabetes may affect stomach fullness. Additionally, it will investigate the relation between demographic and clinical variables and CSA values.\n\nThis research can shed light on diabetes' influence on aspiration risk in pregnancy and evaluate fasting guidelines, underscoring the significance of gastric ultrasound.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "40 Years",
    "healthyVolunteers": true,
    "startDate": "2023-07-26",
    "completionDate": "2023-12-25",
    "primaryCompletionDate": "2023-12-10",
    "firstPostedDate": "2023-07-25",
    "lastUpdatePostedDate": "2023-12-29",
    "locations": [
      {
        "facility": "Sisli Hamidiye Etfal Training and Research Hospital",
        "city": "Sarıyer",
        "state": "Istanbul",
        "country": "Turkey (Türkiye)"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05959135",
    "scrapedAt": "2026-05-14T17:51:05.560Z"
  },
  {
    "nctId": "NCT06912035",
    "briefTitle": "Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang",
    "officialTitle": "EFFICACY OF DIACEREIN ADDITION ON INTERLEUKIN-1Β, HS-CRP, TNF-Α LEVELS AND GLYCEMIC CONTROL IN UNCONTROLLED TYPE 2 DIABETES MELLITUS PATIENTS AT DR. MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG",
    "acronym": null,
    "organization": "Universitas Sriwijaya",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "enrollmentCount": 34,
    "leadSponsor": "Universitas Sriwijaya",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Indonesia Endowment Fund for Education (LPDP), Ministry of Finance Republik of Indonesia"
    ],
    "conditions": [
      "Uncontrolled Diabetes",
      "Diabetes Mellitus Type 2"
    ],
    "interventions": [
      "DRUG: Diacerein 50 mg Capsule",
      "DRUG: Placebo"
    ],
    "briefSummary": "The goal of this clinical trial is to learn if diacerein supplementation can help improve inflammation and glycemic control in adults with uncontrolled type 2 diabetes. It will also study the safety and tolerability of diacerein. The main questions it aims to answer are:\n\n* Does diacerein lower levels of inflammatory markers like interleukin-1β, hs-CRP, and TNF-α?\n* Does diacerein improve blood sugar control?\n* What side effects or problems do participants have when taking diacerein?\n\nResearchers will compare diacerein to a placebo (a look-alike substance with no active drug) to see if it works better for managing type 2 diabetes.\n\nParticipants will:\n\n* Be adults aged 40-60 with uncontrolled type 2 diabetes\n* Take either diacerein or a placebo every day for 12 weeks\n* Visit the clinic for blood tests and monitoring at the beginning and end of the trial\n* Be evaluated for side effects and medication adherence\\]",
    "sex": "ALL",
    "minimumAge": "60 Years",
    "maximumAge": "60 Years",
    "healthyVolunteers": false,
    "startDate": "2024-06-21",
    "completionDate": "2024-11-08",
    "primaryCompletionDate": "2024-11-08",
    "firstPostedDate": "2025-04-04",
    "lastUpdatePostedDate": "2025-04-04",
    "locations": [
      {
        "facility": "Universitas Sriwijaya",
        "city": "Palembang",
        "state": "South Sumatera",
        "country": "Indonesia"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06912035",
    "scrapedAt": "2026-05-14T17:51:05.603Z"
  },
  {
    "nctId": "NCT01973374",
    "briefTitle": "Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy",
    "officialTitle": "Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy",
    "acronym": "Sugar Text",
    "organization": "University of Pennsylvania",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 30,
    "leadSponsor": "University of Pennsylvania",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes in Pregnancy",
      "Gestational Diabetes",
      "Texting Interventions"
    ],
    "interventions": [
      "BEHAVIORAL: Text Message Intervention"
    ],
    "briefSummary": "Maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. Much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. A number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control. This study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes. The study will also assess satisfaction with the intervention itself.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "50 Years",
    "healthyVolunteers": false,
    "startDate": "2013-01",
    "completionDate": "2014-04",
    "primaryCompletionDate": "2014-04",
    "firstPostedDate": "2013-10-31",
    "lastUpdatePostedDate": "2015-02-20",
    "locations": [
      {
        "facility": "Hospital of the University of Pennsylvania",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01973374",
    "scrapedAt": "2026-05-14T17:51:05.645Z"
  },
  {
    "nctId": "NCT02607410",
    "briefTitle": "Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D",
    "officialTitle": "Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes",
    "acronym": null,
    "organization": "University of Sao Paulo General Hospital",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 40,
    "leadSponsor": "University of Sao Paulo General Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Fundação de Amparo à Pesquisa do Estado de São Paulo"
    ],
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: sitagliptin",
      "DRUG: NPH insulin"
    ],
    "briefSummary": "To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin , with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile.",
    "sex": "ALL",
    "minimumAge": "35 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2010-01",
    "completionDate": "2014-07",
    "primaryCompletionDate": "2012-01",
    "firstPostedDate": "2015-11-18",
    "lastUpdatePostedDate": "2015-11-18",
    "locations": [
      {
        "facility": "University of Sao Paulo General Hospital",
        "city": "São Paulo",
        "state": "São Paulo",
        "country": "Brazil"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02607410",
    "scrapedAt": "2026-05-14T17:51:05.688Z"
  },
  {
    "nctId": "NCT07147010",
    "briefTitle": "Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes",
    "officialTitle": "Evaluation of Correlations Between Volatile Organic Compounds (VOCs) Spectra Measured With GC-IMS and MOx-sensors and Venous Blood Glucose in Subjects With Type 2 Diabetes",
    "acronym": "Evo",
    "organization": "DCB Research AG",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "DCB Research AG",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Insel Gruppe AG, University Hospital Bern",
      "BOYDSENSE"
    ],
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "DEVICE: MIB Breath Analyzer"
    ],
    "briefSummary": "The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.\n\nVOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blood glucose levels at different rates of change by administering glucose solution and insulin and by a meal challenge.",
    "sex": "ALL",
    "minimumAge": "45 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2024-10-01",
    "completionDate": "2025-11-27",
    "primaryCompletionDate": "2025-03-30",
    "firstPostedDate": "2025-08-28",
    "lastUpdatePostedDate": "2025-12-09",
    "locations": [
      {
        "facility": "Inselspital Bern",
        "city": "Bern",
        "state": null,
        "country": "Switzerland"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07147010",
    "scrapedAt": "2026-05-14T17:51:05.735Z"
  },
  {
    "nctId": "NCT05191160",
    "briefTitle": "The Soy Treatment Evaluation for Metabolic Health (STEM) Trial",
    "officialTitle": "Role of Soy for Metabolic Health: The Soy Treatment Evaluation for Metabolic Health (STEM) Trial",
    "acronym": null,
    "organization": "University of Toronto",
    "overallStatus": "UNKNOWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 186,
    "leadSponsor": "University of Toronto",
    "sponsorClass": "OTHER",
    "collaborators": [
      "United Soybean Board"
    ],
    "conditions": [
      "Metabolic Syndrome",
      "Overweight and Obesity",
      "PreDiabetes",
      "Diabetes",
      "Healthy Obesity, Metabolically",
      "Overweight",
      "Obesity",
      "Dysglycemia",
      "Cardiovascular Diseases",
      "Heart Disease Risk Factors",
      "Hypertension",
      "Dyslipidemias"
    ],
    "interventions": [
      "OTHER: Soy Milk",
      "OTHER: Cow's Milk",
      "OTHER: Sugar Sweetened Beverages"
    ],
    "briefSummary": "Strategies to reduce sugar-sweetened beverages (SSB) have become one of the leading public health targets to address the epidemics of obesity and diabetes. National food, nutrition, and health policies and programs have positioned low-fat milk as the preferred caloric replacement strategy for SSBs. This strategy derives from evidence that replacement of SSBs with low-fat milk is associated with reductions in weight and incident diabetes in prospective cohort studies and reduces liver fat (an important early metabolic lesion linking obesity to diabetes), as well as triglycerides and blood pressure in randomized trials. Whether these benefits hold for soy milk alternatives is unclear. There is an urgent need for studies to clarify the benefits of soy milk as an alternative to cow's milk. Our overarching aim is to produce high-quality clinical evidence that informs the use of soy as a \"public health intervention\" for addressing the dual epidemics of obesity and diabetes and overall metabolic health. To achieve this aim, we propose to conduct the Soy Treatment Evaluation for Metabolic health (STEM) trial, a large, pragmatic, randomized controlled trial to assess the effect of using 2% soy milk (soy protein vehicle) versus 2% cow's milk (casein and whey vehicle matched for protein and volume) as a \"public health intervention\" to replace SSBs on liver fat and key cardiometabolic mediators/indicators in an at risk population.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "healthyVolunteers": true,
    "startDate": "2021-11-02",
    "completionDate": "2025-03-30",
    "primaryCompletionDate": "2024-10-30",
    "firstPostedDate": "2022-01-13",
    "lastUpdatePostedDate": "2024-04-18",
    "locations": [
      {
        "facility": "Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital",
        "city": "Toronto",
        "state": "Ontario",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05191160",
    "scrapedAt": "2026-05-14T17:51:05.781Z"
  },
  {
    "nctId": "NCT06145360",
    "briefTitle": "Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient",
    "officialTitle": "Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes",
    "acronym": null,
    "organization": "SINA Health Education and Welfare Trust",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 150,
    "leadSponsor": "SINA Health Education and Welfare Trust",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Horizon Pharmaceutical Pvt Ltd"
    ],
    "conditions": [
      "Glucose Metabolism Disorders",
      "Diabetes Mellitus, Type 2",
      "Hypoglycemic Agents",
      "Empagliflozin"
    ],
    "interventions": [
      "DRUG: Empagliflozin 10 MG",
      "DRUG: Insulin+Metformin+DPP4 inhibitor (DPP4I)"
    ],
    "briefSummary": "The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2023-12-01",
    "completionDate": "2024-03-01",
    "primaryCompletionDate": "2024-03-01",
    "firstPostedDate": "2023-11-24",
    "lastUpdatePostedDate": "2024-04-08",
    "locations": [
      {
        "facility": "SINA Shireen Jinnah colony",
        "city": "Karachi",
        "state": null,
        "country": "Pakistan"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06145360",
    "scrapedAt": "2026-05-14T17:51:05.821Z"
  },
  {
    "nctId": "NCT02806960",
    "briefTitle": "A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes",
    "officialTitle": "A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes",
    "acronym": null,
    "organization": "Eli Lilly and Company",
    "overallStatus": "TERMINATED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 12,
    "leadSponsor": "Eli Lilly and Company",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Locemia Solutions ULC"
    ],
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: Nasal Glucagon"
    ],
    "briefSummary": "This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be delivered into the participant's nostril(s) (intranasally) once or twice in each of four study periods. The study is open to adults with type 1 or type 2 diabetes and is expected to last about 50 days for each participant.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2014-06",
    "completionDate": "2014-08",
    "primaryCompletionDate": "2014-06",
    "firstPostedDate": "2016-06-21",
    "lastUpdatePostedDate": "2019-12-13",
    "locations": [
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Mount Royal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT02806960",
    "scrapedAt": "2026-05-14T17:51:05.866Z"
  },
  {
    "nctId": "NCT06273124",
    "briefTitle": "Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes",
    "officialTitle": "Open, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People With Type 1 Diabetes",
    "acronym": null,
    "organization": "Tandem Diabetes Care, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 260,
    "leadSponsor": "Tandem Diabetes Care, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Jaeb Center for Health Research"
    ],
    "conditions": [
      "Type1diabetes"
    ],
    "interventions": [
      "DEVICE: SteadiSet Extended Wear Infusion Set"
    ],
    "briefSummary": "The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).\n\nParticipants will be asked to:\n\n1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods\n2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2024-03-07",
    "completionDate": "2024-12-11",
    "primaryCompletionDate": "2024-12-11",
    "firstPostedDate": "2024-02-22",
    "lastUpdatePostedDate": "2025-09-24",
    "locations": [
      {
        "facility": "Hoag Memorial Hospital Presbyterian",
        "city": "Newport Beach",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Stanford University",
        "city": "Stanford",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Barbara Davis Center",
        "city": "Aurora",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "Endocrine Research Solutions",
        "city": "Roswell",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "Rocky Mountain Clinical Research",
        "city": "Idaho Falls",
        "state": "Idaho",
        "country": "United States"
      },
      {
        "facility": "Northwestern University",
        "city": "Evanston",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "Massachusetts General Hospital",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "Henry Ford Health System",
        "city": "Detroit",
        "state": "Michigan",
        "country": "United States"
      },
      {
        "facility": "International Diabetes Center - HealthPartners Institute",
        "city": "Minneapolis",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Mayo Clinic",
        "city": "Rochester",
        "state": "Minnesota",
        "country": "United States"
      },
      {
        "facility": "Icahn School of Medicine at Mt. Sinai",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "SUNY Upstate Medical University",
        "city": "Syracuse",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "Texas Diabetes and Endocrinology",
        "city": "Austin",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "Rainier Clinical Research Center",
        "city": "Renton",
        "state": "Washington",
        "country": "United States"
      },
      {
        "facility": "University of Washington",
        "city": "Seattle",
        "state": "Washington",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT06273124",
    "scrapedAt": "2026-05-14T17:51:05.902Z"
  },
  {
    "nctId": "NCT07139964",
    "briefTitle": "High-Dose Vitamin D3 for Diabetic Foot Ulcer Healing: Randomized Controlled Trial",
    "officialTitle": "Effectiveness of High-Dose Vitamin D3 in Improving Diabetic Foot Ulcer Healing by Reducing the MMP-9 to TIMP-1 Ratio: Randomized Double-Blind Placebo-Controlled Trial",
    "acronym": "DFU",
    "organization": "Universitas Sriwijaya",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 24,
    "leadSponsor": "Universitas Sriwijaya",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetic Foot Ulcer",
      "Vitamin D Deficiency",
      "Wound Healing Disorder"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Vitamin D3",
      "OTHER: Placebo"
    ],
    "briefSummary": "This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of high-dose vitamin D3 supplementation in improving diabetic foot ulcer (DFU) healing. DFUs are common, serious complications of diabetes, often associated with delayed wound healing due to persistent inflammation, impaired angiogenesis, and imbalances between matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1). Vitamin D deficiency is prevalent among DFU patients and is linked to impaired fibroblast function, poor angiogenesis, and increased inflammation.\n\nParticipants with DFUs and serum vitamin D levels \\<30 ng/mL will be randomized to receive either 10,000 IU oral vitamin D3 daily or placebo for 28 days, in addition to standard DFU care. Primary outcomes include changes in tissue MMP-9/TIMP-1 expression ratio and wound healing progression. The study will provide evidence on whether high-dose vitamin D3 can serve as a safe, effective adjunctive therapy in DFU management.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2024-07-01",
    "completionDate": "2025-07-31",
    "primaryCompletionDate": "2025-01-31",
    "firstPostedDate": "2025-08-24",
    "lastUpdatePostedDate": "2025-08-24",
    "locations": [
      {
        "facility": "Dr. Mohammad Hoesin General Hospital",
        "city": "Palembang",
        "state": "South Sumatra",
        "country": "Indonesia"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07139964",
    "scrapedAt": "2026-05-14T17:51:05.981Z"
  },
  {
    "nctId": "NCT02776098",
    "briefTitle": "Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance",
    "officialTitle": "Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance",
    "acronym": null,
    "organization": "Children's Hospital of Philadelphia",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 54,
    "leadSponsor": "Children's Hospital of Philadelphia",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Institutes of Health (NIH)",
      "University of Pennsylvania",
      "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
    ],
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [],
    "briefSummary": "This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the presence of glucose intolerance. This is a longitudinal cohort study of 3 main groups: CF subjects without Cystic Fibrosis-related diabetes (CFRD), healthy matched controls and CF subjects with newly diagnosed CFRD started on insulin therapy.",
    "sex": "ALL",
    "minimumAge": "12 Years",
    "maximumAge": null,
    "healthyVolunteers": true,
    "startDate": "2016-05",
    "completionDate": "2024-03-04",
    "primaryCompletionDate": "2024-03-04",
    "firstPostedDate": "2016-05-18",
    "lastUpdatePostedDate": "2024-03-07",
    "locations": [
      {
        "facility": "Children's Hospital of Philadelphia",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "University of Pennsylvania",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02776098",
    "scrapedAt": "2026-05-14T17:51:06.023Z"
  },
  {
    "nctId": "NCT02423798",
    "briefTitle": "New Generation Enlite Accuracy Study",
    "officialTitle": "Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home",
    "acronym": null,
    "organization": "Medtronic MiniMed, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 24,
    "leadSponsor": "Medtronic MiniMed, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Profil Institut für Stoffwechselforschung GmbH"
    ],
    "conditions": [
      "Diabetes"
    ],
    "interventions": [
      "DEVICE: Glucose sensor (Enlite)"
    ],
    "briefSummary": "The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components.\n\nTo evaluate the accuracy and performance of the new generation Enlite sensor. This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial.\n\nThe trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and self-monitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "74 Years",
    "healthyVolunteers": false,
    "startDate": "2015-04",
    "completionDate": "2015-09",
    "primaryCompletionDate": "2015-09",
    "firstPostedDate": "2015-04-22",
    "lastUpdatePostedDate": "2018-01-17",
    "locations": [],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT02423798",
    "scrapedAt": "2026-05-14T17:51:06.079Z"
  },
  {
    "nctId": "NCT02589314",
    "briefTitle": "Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2",
    "officialTitle": "Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2",
    "acronym": null,
    "organization": "University of Brasilia",
    "overallStatus": "TERMINATED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 90,
    "leadSponsor": "University of Brasilia",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Catholic University of Brasília",
      "Brasilia University Hospital"
    ],
    "conditions": [
      "Chronic Periodontitis",
      "Diabetes Type 2"
    ],
    "interventions": [
      "DEVICE: Mechanical periodontal therapy",
      "PROCEDURE: nonsurgical periodontal therapy"
    ],
    "briefSummary": "This study will evaluate if periodontal mechanical treatment is capable to alter immunological and genetical parameters related to systemic health in patients with chronic periodontitis ant diabetes type 2.",
    "sex": "ALL",
    "minimumAge": "30 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": true,
    "startDate": "2015-11",
    "completionDate": "2020-08",
    "primaryCompletionDate": "2019-09",
    "firstPostedDate": "2015-10-28",
    "lastUpdatePostedDate": "2020-08-24",
    "locations": [
      {
        "facility": "Priscilla Farias Naiff",
        "city": "Brasília",
        "state": "Federal District",
        "country": "Brazil"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02589314",
    "scrapedAt": "2026-05-14T17:51:06.094Z"
  },
  {
    "nctId": "NCT00993304",
    "briefTitle": "A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics",
    "officialTitle": "A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes",
    "acronym": null,
    "organization": "Novo Nordisk A/S",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "Novo Nordisk A/S",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: liraglutide",
      "DRUG: placebo"
    ],
    "briefSummary": "This trial is conducted in Europe. The aim of this trial is to investigate whether a new compound, liraglutide, reduces the level of lipids (fat), including cholesterol, in the blood of type 2 diabetics, following a meal with high fat content.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2009-10",
    "completionDate": "2010-12",
    "primaryCompletionDate": "2010-12",
    "firstPostedDate": "2009-10-12",
    "lastUpdatePostedDate": "2017-01-26",
    "locations": [
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Aarhus C",
        "state": null,
        "country": "Denmark"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00993304",
    "scrapedAt": "2026-05-14T17:51:06.125Z"
  },
  {
    "nctId": "NCT00312104",
    "briefTitle": "Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes",
    "officialTitle": "Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.",
    "acronym": null,
    "organization": "Novo Nordisk A/S",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 325,
    "leadSponsor": "Novo Nordisk A/S",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "DRUG: insulin detemir",
      "DRUG: insulin glargine",
      "DRUG: insulin aspart"
    ],
    "briefSummary": "The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2002-04",
    "completionDate": "2003-03",
    "primaryCompletionDate": "2003-03",
    "firstPostedDate": "2006-04-07",
    "lastUpdatePostedDate": "2017-01-27",
    "locations": [
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Graz",
        "state": null,
        "country": "Austria"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Vienna",
        "state": null,
        "country": "Austria"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Vienna",
        "state": null,
        "country": "Austria"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Vienna",
        "state": null,
        "country": "Austria"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Vienna",
        "state": null,
        "country": "Austria"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Bad Kreuznach",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Bad Mergentheim",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Bad Neuenahr-Ahrweiler",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Berlin",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Diez",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Erlangen",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Essen",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Flensburg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Frankfurt",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Friedrichsthal",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Genthin",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Halle",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Hamburg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Hanover",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Heidelberg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Hennigsdorf",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Hünxe",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Jena",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kiel",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Landau",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Ludwigshafen",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Marl",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Mönchengladbach",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Neunkirchen",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Neuss",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Northeim",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Nuremberg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Rehlingen-Siersburg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Rheda-Wiedenbrück",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Saarbrücken",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Saarlouis",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Schönebeck",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Schwabenheim",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Schwerin",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Völklingen",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Wiesbaden",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Würzburg",
        "state": null,
        "country": "Germany"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Johannesburg",
        "state": "Gauteng",
        "country": "South Africa"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Durban",
        "state": "KwaZulu-Natal",
        "country": "South Africa"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Cape Town",
        "state": "Western Cape",
        "country": "South Africa"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Cape Town",
        "state": "Western Cape",
        "country": "South Africa"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00312104",
    "scrapedAt": "2026-05-14T17:51:06.174Z"
  },
  {
    "nctId": "NCT01075347",
    "briefTitle": "Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries",
    "officialTitle": "Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries",
    "acronym": null,
    "organization": "National Taiwan University Hospital",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 165,
    "leadSponsor": "National Taiwan University Hospital",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Corneal Epithelial Defect",
      "Diabetic Retinopathy",
      "Penetrating Keratoplasty"
    ],
    "interventions": [
      "OTHER: autologous serum",
      "OTHER: Non-autologous serum"
    ],
    "briefSummary": "Ophthalmology ,cornea Autologous serum has long been known to be effective to promote corneal epithelial wound healing in a variety of ocular surface disorders. However, its effectiveness for corneal epithelial defects due to pars plana vitrectomy (PPV) for diabetic retinopathy and penetrating keratoplasty has seldom been reported. In this study, we plan to perform a prospective study to determine the effectiveness of topical autologous serum as a primary treatment for corneal epithelial defect in patients undergoing vitrectomy for diabetic retinopathy and penetrating keratoplasty. All patients enrolled in this study have received corneal epithelial debridement at the end of the ocular surgeries, namely PPV for diabetic retinopathy and penetrating keratoplasty. The patients were grouped into two treatment groups. In the control group, the patients receive conventional postoperative eye drops including topical steroid, antibiotic and mydriatics. In the experimental group, the patients receive topical autologous serum eye drops in addition to conventional postoperative eye drops. The duration for cornea surface to completely re-epithelize, the incidence of corneal complications due to delayed surface re-epithelization (e.g. infectious corneal ulcer, corneal melting, sterile corneal ulcer, corneal neovascularization), and the incidence of recurrent epithelial break down after initial epithelization will be compared between these two groups. Patients undergoing PPV for diabetic retinopathy and penetrating keratoplasty will be compared separately",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": true,
    "startDate": "2007-03",
    "completionDate": "2008-03",
    "primaryCompletionDate": "2008-03",
    "firstPostedDate": "2010-02-25",
    "lastUpdatePostedDate": "2010-09-14",
    "locations": [
      {
        "facility": "National Taiwan University Hospital, department of Ophthalmology",
        "city": "Taipei",
        "state": "Taiwan",
        "country": "Taiwan"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT01075347",
    "scrapedAt": "2026-05-14T17:51:06.191Z"
  },
  {
    "nctId": "NCT05874726",
    "briefTitle": "Biological Sample Repository for Gastrointestinal Disorders",
    "officialTitle": "Biological Sample Repository for Gastrointestinal Disorders",
    "acronym": null,
    "organization": "Brigham and Women's Hospital",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 500,
    "leadSponsor": "Pichamol Jirapinyo, MD, MPH",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Tufts University",
      "Boston Children's Hospital",
      "Mayo Clinic"
    ],
    "conditions": [
      "Obesity",
      "Obesity, Morbid",
      "Obesity, Primary",
      "Gastro-Intestinal Disorder",
      "Overweight and Obesity",
      "Overweight",
      "Overweight or Obesity",
      "Diabetes Type 2",
      "Diabetes Mellitus",
      "Diabetes Mellitus, Type 2",
      "Hypertension",
      "Hyperlipidemias",
      "Sleep Apnea",
      "GERD",
      "Gastroesophageal Reflux",
      "Musculoskeletal Pain Disorder",
      "Cancer"
    ],
    "interventions": [
      "DIAGNOSTIC_TEST: Blood Collection",
      "DIAGNOSTIC_TEST: Urine Collection",
      "DIAGNOSTIC_TEST: Tissue Sample Collection"
    ],
    "briefSummary": "The goal of this observational study has the purpose of collecting biological samples from obese patients undergoing evaluation for weight loss by means of medical or endoscopic therapies; and of post bariatric surgery patients presenting with short- and long-term surgical complications. The aim is to enhance the overall understanding of the mechanisms leading to obesity, weight loss, failure to lose weight, and weight regain following treatment. Additional goals are to determine the efficacy of endoscopic and surgical procedures, to identify potential therapeutic targets and disease biomarkers that predict response to therapy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2023-07-19",
    "completionDate": "2029-04",
    "primaryCompletionDate": "2028-07",
    "firstPostedDate": "2023-05-25",
    "lastUpdatePostedDate": "2025-12-02",
    "locations": [
      {
        "facility": "Brigham and Women's Hospital",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05874726",
    "scrapedAt": "2026-05-14T17:51:06.235Z"
  },
  {
    "nctId": "NCT00741026",
    "briefTitle": "A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers",
    "officialTitle": "A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers",
    "acronym": null,
    "organization": "Milton S. Hershey Medical Center",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 15,
    "leadSponsor": "Milton S. Hershey Medical Center",
    "sponsorClass": "OTHER",
    "collaborators": [
      "American Medical Association"
    ],
    "conditions": [
      "Insulin Resistance",
      "Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: Olanzapine 10 mg po qhs for 3 days",
      "DRUG: Placebo"
    ],
    "briefSummary": "The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunteers. These questions will be answered by having volunteers undergo two glucose tolerance tests in a crossover study design.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "30 Years",
    "healthyVolunteers": true,
    "startDate": "2008-08",
    "completionDate": "2011-05",
    "primaryCompletionDate": "2010-12",
    "firstPostedDate": "2008-08-25",
    "lastUpdatePostedDate": "2014-07-14",
    "locations": [
      {
        "facility": "Penn State College of Medicine, Penn State Milton S. Hershey Medical Center",
        "city": "Hershey",
        "state": "Pennsylvania",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT00741026",
    "scrapedAt": "2026-05-14T17:51:06.252Z"
  },
  {
    "nctId": "NCT04532385",
    "briefTitle": "Effect of Green Tea Extract on Lipids in Patients With Type 2 Diabetes",
    "officialTitle": "Effect of a 12-week Administration of Green Tea Extract on Lipids in Patients With Type 2 Diabetes",
    "acronym": "HDL",
    "organization": "Centro Universitario de Ciencias de la Salud, Mexico",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "Centro Universitario de Ciencias de la Salud, Mexico",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes Mellitus, Type 2",
      "Dyslipidemias",
      "Arterial Stiffness"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Green tea extract",
      "DIETARY_SUPPLEMENT: Placebo"
    ],
    "briefSummary": "The main objectives of this study were to evaluate the effect of a 12-week supplementation with GTE (400 mg every 12 hours) on serum lipids, arterial stiffness and inflammatory cytokines in patients with T2DM.",
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2018-06-12",
    "completionDate": "2019-01-14",
    "primaryCompletionDate": "2019-01-14",
    "firstPostedDate": "2020-08-31",
    "lastUpdatePostedDate": "2020-08-31",
    "locations": [
      {
        "facility": "Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara",
        "city": "Guadalajara",
        "state": "Jalisco",
        "country": "Mexico"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04532385",
    "scrapedAt": "2026-05-14T17:51:06.273Z"
  },
  {
    "nctId": "NCT00108615",
    "briefTitle": "Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance",
    "officialTitle": "Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance",
    "acronym": null,
    "organization": "VA Office of Research and Development",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 48,
    "leadSponsor": "US Department of Veterans Affairs",
    "sponsorClass": "FED",
    "collaborators": [],
    "conditions": [
      "Glucose Metabolism Disorders",
      "Diabetes"
    ],
    "interventions": [
      "DRUG: Metformin",
      "DRUG: Pioglitazone",
      "DRUG: Metformin",
      "DRUG: Pioglitazone",
      "RADIATION: CT scans",
      "PROCEDURE: Oral glucose tolerance test"
    ],
    "briefSummary": "Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.",
    "sex": "ALL",
    "minimumAge": "35 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": true,
    "startDate": "2004-01",
    "completionDate": "2007-12",
    "primaryCompletionDate": "2007-04",
    "firstPostedDate": "2005-04-18",
    "lastUpdatePostedDate": "2008-04-25",
    "locations": [
      {
        "facility": "Central Arkansas Veterans HCS",
        "city": "Little Rock",
        "state": "Arkansas",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00108615",
    "scrapedAt": "2026-05-14T17:51:06.318Z"
  },
  {
    "nctId": "NCT05232708",
    "briefTitle": "A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide",
    "officialTitle": "A Study to Demonstrate Bioequivalence Between Semaglutide Formulation for the DV3396 Pen-injector and the Formulation for the PDS290 Semaglutide Pen-injector",
    "acronym": null,
    "organization": "Novo Nordisk A/S",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 18,
    "leadSponsor": "Novo Nordisk A/S",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Healthy Volunteers (Diabetes Mellitus, Type 2)"
    ],
    "interventions": [
      "DRUG: Semaglutide B, 1.34 mg/mL",
      "DRUG: Semaglutide D, 1.0 mg/mL",
      "DRUG: Semaglutide D, 1.0 mg/mL",
      "DRUG: Semaglutide B, 1.34 mg/mL"
    ],
    "briefSummary": "In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg). The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each period. Participants will have to fast for at least 6 hours overnight with only water allowed before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1 and Period 2.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "55 Years",
    "healthyVolunteers": true,
    "startDate": "2022-01-19",
    "completionDate": "2022-08-30",
    "primaryCompletionDate": "2022-08-30",
    "firstPostedDate": "2022-02-10",
    "lastUpdatePostedDate": "2024-01-26",
    "locations": [
      {
        "facility": "Parexel CPRU, Level 7",
        "city": "Harrow",
        "state": "Middlesex",
        "country": "United Kingdom"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05232708",
    "scrapedAt": "2026-05-14T17:51:06.348Z"
  },
  {
    "nctId": "NCT00641407",
    "briefTitle": "Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes",
    "officialTitle": "Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial",
    "acronym": null,
    "organization": "University of Campania Luigi Vanvitelli",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 100,
    "leadSponsor": "University of Campania Luigi Vanvitelli",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus",
      "Hypoglycemia"
    ],
    "interventions": [
      "DRUG: NPL insulin",
      "DRUG: Insulin glargine"
    ],
    "briefSummary": "The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added when glycemic control with a regimen of oral antidiabetic agents becomes suboptimal.\n\nThe aims of the present study were: 1) To compare the clinical efficacy of insulin glargine and neutral protamine lispro (NPL) insulin when added to ongoing oral therapy in poorly controlled type 2 diabetic patients; 2) to find out the possibility to phenotype the patient who may benefit more by the single treatment.\n\nThis an open-label, randomized, parallel, 36-week comparative study was performed between January 2007 and March 2008 at a single centre.",
    "sex": "ALL",
    "minimumAge": "30 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": false,
    "startDate": "2007-01",
    "completionDate": "2008-03",
    "primaryCompletionDate": "2007-12",
    "firstPostedDate": "2008-03-24",
    "lastUpdatePostedDate": "2008-03-31",
    "locations": [
      {
        "facility": "Department of Geriatrics and Metabolic Disease",
        "city": "Naples",
        "state": null,
        "country": "Italy"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00641407",
    "scrapedAt": "2026-05-14T17:51:06.386Z"
  },
  {
    "nctId": "NCT04082000",
    "briefTitle": "Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy",
    "officialTitle": "A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy",
    "acronym": null,
    "organization": "Breath of Life International Pharma Ltd",
    "overallStatus": "TERMINATED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "enrollmentCount": 2,
    "leadSponsor": "Breath of Life International Pharma Ltd",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetic Neuropathy"
    ],
    "interventions": [
      "DRUG: BOL-DP-o-04",
      "DRUG: Placebo"
    ],
    "briefSummary": "This is a randomized, double-blind, placebo-controlled Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2019-04-15",
    "completionDate": "2020-11-04",
    "primaryCompletionDate": "2020-11-04",
    "firstPostedDate": "2019-09-09",
    "lastUpdatePostedDate": "2021-03-24",
    "locations": [
      {
        "facility": "Wolfson Medical Center",
        "city": "Holon",
        "state": null,
        "country": "Israel"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04082000",
    "scrapedAt": "2026-05-14T17:51:06.429Z"
  },
  {
    "nctId": "NCT07515807",
    "briefTitle": "Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence",
    "officialTitle": "Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence",
    "acronym": "QCRC-AI",
    "organization": "Weill Cornell Medical College in Qatar",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 10000,
    "leadSponsor": "Weill Cornell Medical College in Qatar",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Hamad Medical Corporation"
    ],
    "conditions": [
      "Cardio Vascular Disease",
      "Acute Coronary Syndromes (ACS)",
      "Type 2 Diabetes",
      "Pre Diabetes",
      "Artifical Intelligence"
    ],
    "interventions": [],
    "briefSummary": "Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2026-07-16",
    "completionDate": "2030-07-16",
    "primaryCompletionDate": "2030-07-16",
    "firstPostedDate": "2026-04-07",
    "lastUpdatePostedDate": "2026-04-21",
    "locations": [
      {
        "facility": "Hamad Medical Corporation",
        "city": "Doha",
        "state": null,
        "country": "Qatar"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07515807",
    "scrapedAt": "2026-05-14T17:51:06.447Z"
  },
  {
    "nctId": "NCT01847092",
    "briefTitle": "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria",
    "officialTitle": "An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria",
    "acronym": null,
    "organization": "Ardelyx",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 154,
    "leadSponsor": "Ardelyx",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "AstraZeneca"
    ],
    "conditions": [
      "Chronic Kidney Disease",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: AZD1722",
      "DRUG: Placebo"
    ],
    "briefSummary": "The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2013-05",
    "completionDate": "2015-04",
    "primaryCompletionDate": "2015-03",
    "firstPostedDate": "2013-05-06",
    "lastUpdatePostedDate": "2020-05-27",
    "locations": [
      {
        "facility": "Creekside Endocrine Associates PC",
        "city": "Denver",
        "state": "Colorado",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT01847092",
    "scrapedAt": "2026-05-14T17:51:06.482Z"
  },
  {
    "nctId": "NCT00958711",
    "briefTitle": "The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer",
    "officialTitle": "The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer",
    "acronym": null,
    "organization": "Baxter Healthcare Corporation",
    "overallStatus": "TERMINATED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 90,
    "leadSponsor": "Baxter Healthcare Corporation",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Synovis Surgical Innovations"
    ],
    "conditions": [
      "Diabetic Foot Ulcers"
    ],
    "interventions": [
      "DEVICE: Unite Biomatrix",
      "OTHER: Saline and Gauze"
    ],
    "briefSummary": "The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2009-01",
    "completionDate": "2012-05",
    "primaryCompletionDate": "2012-05",
    "firstPostedDate": "2009-08-13",
    "lastUpdatePostedDate": "2019-12-18",
    "locations": [
      {
        "facility": "University of California - San Diego",
        "city": "San Diego",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "University of Miami, Miller School of Medicine",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Aiyan Diabetes Center",
        "city": "Evans",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "Foot & Ankle Associates of Central Illinois, LLC",
        "city": "Springfield",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "Eastern Carolina Foot and Ankle",
        "city": "Greenville",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "Foot and Ankle East",
        "city": "Greenville",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "Carolina East Family Medicine",
        "city": "Greenville",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "Family Foot & Ankle Physicians",
        "city": "Greenville",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "Comprehensive Wound Care Thoracic & Vascular Associates of Kinston P.A.",
        "city": "Kinston",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "The Foot & Ankle Associates of North Carolina, PLLC",
        "city": "Rocky Mount",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "Martin Foot and Ankle",
        "city": "York",
        "state": "Pennsylvania",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT00958711",
    "scrapedAt": "2026-05-14T17:51:06.515Z"
  },
  {
    "nctId": "NCT00198471",
    "briefTitle": "Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment",
    "officialTitle": "An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy",
    "acronym": null,
    "organization": "Bausch & Lomb Incorporated",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 10,
    "leadSponsor": "Bausch & Lomb Incorporated",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Vitreous Detachment",
      "Diabetic Retinopathy"
    ],
    "interventions": [
      "DRUG: Vitrase"
    ],
    "briefSummary": "The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.",
    "sex": "ALL",
    "minimumAge": "50 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2005-07",
    "completionDate": "2006-11",
    "primaryCompletionDate": "2006-11",
    "firstPostedDate": "2005-09-20",
    "lastUpdatePostedDate": "2013-03-15",
    "locations": [
      {
        "facility": "Edgar L. Thomas, MD",
        "city": "Beverly Hills",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "Ronni Lieberman, MD",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "Valley Retina Institute, PA",
        "city": "McAllen",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "The Virginia Retina Center",
        "city": "Leesburg",
        "state": "Virginia",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00198471",
    "scrapedAt": "2026-05-14T17:51:06.551Z"
  },
  {
    "nctId": "NCT03248271",
    "briefTitle": "Effects of Insulin on Hypotension and Sarcopenia",
    "officialTitle": "Effects of Insulin on Hypotension and Sarcopenia",
    "acronym": null,
    "organization": "University of British Columbia",
    "overallStatus": "WITHDRAWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 0,
    "leadSponsor": "Kenneth Madden",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Sarcopenia",
      "Hypotension, Orthostatic"
    ],
    "interventions": [
      "DRUG: Insulin Lispro"
    ],
    "briefSummary": "In this study investigator's aim to determine the impact of insulin therapy on hypotension and sarcopenia",
    "sex": "ALL",
    "minimumAge": "65 Years",
    "maximumAge": null,
    "healthyVolunteers": null,
    "startDate": "2017-10-01",
    "completionDate": "2023-01-10",
    "primaryCompletionDate": "2023-01-10",
    "firstPostedDate": "2017-08-14",
    "lastUpdatePostedDate": "2023-01-12",
    "locations": [
      {
        "facility": "University of British Columbia - Gerontology Research Lab",
        "city": "Vancouver",
        "state": "British Columbia",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03248271",
    "scrapedAt": "2026-05-14T17:51:06.623Z"
  },
  {
    "nctId": "NCT01705899",
    "briefTitle": "Islet Allotransplantation in Type 1 Diabetes",
    "officialTitle": "Islet Allotransplantation in Type 1 Diabetes",
    "acronym": null,
    "organization": "Ohio State University",
    "overallStatus": "SUSPENDED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "Ohio State University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DRUG: Human Pancreatic Islets"
    ],
    "briefSummary": "Islet transplantation can provide physiologic insulin replacement to patients with type 1 diabetes without the complications associated with whole pancreas transplantation. The purpose of this study is to achieve insulin-independence in patients with type 1 diabetes, thereby eliminating the need for exogenous insulin injections to maintain normal glucose levels, ameliorating severe hypoglycemia and potentially decreasing the development of diabetes-related complications. This study will investigate islet transplantation in subjects who have preserved renal function and subjects who have undergone cadaveric renal transplantation, since the latter subjects are already on immunosuppression.\n\nThis is a single center, prospective trial of islet transplantation in subjects receiving islets alone or islets after kidney transplant. This is a phase I study investigating the use of islet transplantation for the treatment of type 1 diabetes. Subjects will be eligible for an islet transplant if they meet all of the inclusion criteria and none of the exclusion criteria outlined in the protocol. In brief, the aims of this study are to establish an islet transplant program at the Ohio State University, determine the safety of islet transplantation in islet alone and kidney transplant recipients, determine whether islet transplantation will reduce the frequency of severe hypoglycemic events, determine whether a novel steroid-free immunosuppressive protocol will prevent rejection in islet transplants and to achieve insulin independence at one year after the final islet transplant.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2006-11",
    "completionDate": "2033-10",
    "primaryCompletionDate": "2033-10",
    "firstPostedDate": "2012-10-12",
    "lastUpdatePostedDate": "2025-01-16",
    "locations": [
      {
        "facility": "The Ohio State University Medical Center",
        "city": "Columbus",
        "state": "Ohio",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01705899",
    "scrapedAt": "2026-05-14T17:51:06.662Z"
  },
  {
    "nctId": "NCT06103799",
    "briefTitle": "Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients",
    "officialTitle": "Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients: A Randomised Controlled Trial",
    "acronym": null,
    "organization": "The Dental Hospital of Zhejiang University School of Medicine",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 32,
    "leadSponsor": "The Dental Hospital of Zhejiang University School of Medicine",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Bone Resorption",
      "Diabetes"
    ],
    "interventions": [
      "BEHAVIORAL: IMB model-based continuity of care"
    ],
    "briefSummary": "The investigators recruited 32 diabetic IOD patients with a total of 110 problematic implants who had completed the treatment for peri-implantitis between January 2021 and March 2023 as research subjects. The patients were randomly assigned to the control group or the experimental group using the random number table. The control group received routine postoperative medical advice, whereas the experimental group was given an IMB model-based continuity of care.",
    "sex": "ALL",
    "minimumAge": null,
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2023-01-01",
    "completionDate": "2023-09-30",
    "primaryCompletionDate": "2023-09-20",
    "firstPostedDate": "2023-10-27",
    "lastUpdatePostedDate": "2023-10-27",
    "locations": [
      {
        "facility": "The Stomatologic Hospital, School of Medicine, Zhejiang University",
        "city": "Hangzhou",
        "state": "Zhejiang",
        "country": "China"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06103799",
    "scrapedAt": "2026-05-14T17:51:06.702Z"
  },
  {
    "nctId": "NCT06474598",
    "briefTitle": "An Adaptive Design Study of MTX228",
    "officialTitle": "A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function",
    "acronym": null,
    "organization": "University of Alberta",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "enrollmentCount": 24,
    "leadSponsor": "University of Alberta",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: MTX228",
      "DEVICE: DEXCOM G6"
    ],
    "briefSummary": "MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study.\n\nThe purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2024-11-14",
    "completionDate": "2027-12",
    "primaryCompletionDate": "2026-10",
    "firstPostedDate": "2024-06-25",
    "lastUpdatePostedDate": "2026-04-13",
    "locations": [
      {
        "facility": "University of Alberta",
        "city": "Edmonton",
        "state": "Alberta",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT06474598",
    "scrapedAt": "2026-05-14T17:51:06.885Z"
  },
  {
    "nctId": "NCT05316298",
    "briefTitle": "Diabetic Foot Osteomyelitis Treatment Using Gentamicin-loaded Calcium Sulfate-hydroxyapatite Biocomposite",
    "officialTitle": "Gentamicin-loaded Calcium Sulfate-hydroxyaPatite Biocomposite to tREat Diabetic Foot Ulcers Complicated by oSteomyElitis: a pRospectiVE Cohort Study",
    "acronym": "PRESERVE",
    "organization": "University Medical Center Groningen",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 182,
    "leadSponsor": "University Medical Center Groningen",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Ziekenhuisgroep Twente",
      "Slingeland Hospital",
      "Franciscus Gasthuis",
      "UMC Utrecht",
      "Rijnstate Hospital",
      "Jeroen Bosch Ziekenhuis",
      "Reinier de Graaf Groep",
      "St. Antonius Hospital",
      "St Jansdal Hospital",
      "Maasstad Hospital"
    ],
    "conditions": [
      "Diabetic Foot Ulcer",
      "Osteomyelitis",
      "Diabetes Mellitus"
    ],
    "interventions": [],
    "briefSummary": "The amputation risk is high when diabetic foot ulcers, complicated by osteomyelitis, fail to heal after non-surgical standard-of-care treatment. A new treatment regimen has been developed recently and has been proven feasible. This treatment regimen consists of surgical debridement, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, in combination with antibiotic therapy and offloading. This treatment regimen has not been investigated prospectively.\n\nTherefore, this multicenter prospective cohort study was designed, with the primary objective of investigating postoperative wound healing. Patients with diabetic forefoot ulcers, complicated by osteomyelitis, will be included. The most relevant exclusion criteria are: Severe diabetic foot infection, severe limb ischemia, and foot deformity causing high pressure and friction on the diabetic foot ulcer. After inclusion, subjects will undergo study phase 1, which is observation of the standard-of-care non-surgical treatment. When standard-of-care non-surgical treatment is unsuccessful, subjects will be included in study phase 2, which consists of treatment by surgical debridement of the diabetic foot ulcer and underlying osteomyelitis, followed by bone void filling with gentamicin-loaded calcium sulfate-hydroxyapatite biocomposite and closure of soft tissues and skin, followed by a postoperatieve treatment regimen which involves wound care, 10 days of antibiotic therapy and offloading.\n\nThe primary outcome measure of this study is the proportion of subjects with post-operative wound healing, which will be investigated clinically and will be objectified by a review panel of blinded, independent experts based on digital photographs. Follow-up will be performed until wound healing or for a maximum of 20 weeks. The primary outcome measure is the proportion of subjects with postoperative wound healing during 20 weeks of follow-up. Secondary outcome measures are: days until postoperative wound healing, proportion of subjects with persistent osteomyelitis post-operatively, proportion of subjects undergoing amputations during follow-up, foot function index scores at inclusion and after 20 weeks follow-up.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2022-12-01",
    "completionDate": "2025-01-01",
    "primaryCompletionDate": "2025-01-01",
    "firstPostedDate": "2022-04-07",
    "lastUpdatePostedDate": "2022-11-16",
    "locations": [
      {
        "facility": "Jeroen Bosch Hospital",
        "city": "'s-Hertogenbosch",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Hospitalgroup Twente",
        "city": "Almelo",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Rijnstate Hospital",
        "city": "Arnhem",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Reinier de Graaf Hospital",
        "city": "Delft",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Slingeland Hospital",
        "city": "Doetinchem",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "St. Jansdal Hospital",
        "city": "Harderwijk",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "St. Antonius Hospital",
        "city": "Nieuwegein",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Franciscus Gasthuis & Vlietland",
        "city": "Rotterdam",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "Maasstad Hospital",
        "city": "Rotterdam",
        "state": null,
        "country": "Netherlands"
      },
      {
        "facility": "University Medical Center Utrecht",
        "city": "Utrecht",
        "state": null,
        "country": "Netherlands"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05316298",
    "scrapedAt": "2026-05-14T17:51:06.927Z"
  },
  {
    "nctId": "NCT07387393",
    "briefTitle": "To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years",
    "officialTitle": "Peau o le Vasa: Accelerating the Currents of Health Advances for Pasifika People",
    "acronym": null,
    "organization": "University of Hawaii",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 400,
    "leadSponsor": "University of Hawaii",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Association of Pasifika Organizations",
      "Papa Ola Lōkahi",
      "National Heart, Lung, and Blood Institute (NHLBI)"
    ],
    "conditions": [
      "Cardiometabolic Conditions",
      "Hypertension (HTN)",
      "Dyslipidemia",
      "Pre-diabetes",
      "Type 2 Diabetes Mellitus (T2DM)",
      "Overweight (BMI > 25)",
      "Weight Loss Trial"
    ],
    "interventions": [
      "BEHAVIORAL: PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program"
    ],
    "briefSummary": "In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period.\n\nThe aims of this study are threefold:\n\n1. To evaluate the implementation of the PPP across multiple community sites using a Type 3 hybrid effectiveness-implementation design guided by established frameworks such as RE-AIM and PRISM.\n2. To examine participant-level outcomes associated with PPP implementation, including changes in cardiometabolic risk factors, health behaviors, and SDOH factors from baseline to 3 and 9-month follow-up.\n3. To evaluate the cost and cost-effectiveness of implementing the PPP across community settings.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2026-05-01",
    "completionDate": "2028-10-31",
    "primaryCompletionDate": "2028-09-15",
    "firstPostedDate": "2026-02-04",
    "lastUpdatePostedDate": "2026-04-22",
    "locations": [
      {
        "facility": "National Association of Pasifika Organizations",
        "city": "Fayetteville",
        "state": "Arkansas",
        "country": "United States"
      },
      {
        "facility": "Papa Ola Lokahi",
        "city": "Honolulu",
        "state": "Hawaii",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07387393",
    "scrapedAt": "2026-05-14T17:51:06.994Z"
  },
  {
    "nctId": "NCT00408993",
    "briefTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",
    "officialTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China",
    "acronym": null,
    "organization": "Eli Lilly and Company",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 215,
    "leadSponsor": "Eli Lilly and Company",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Boehringer Ingelheim"
    ],
    "conditions": [
      "Diabetic Neuropathies"
    ],
    "interventions": [
      "DRUG: Duloxetine Hydrochloride",
      "DRUG: Placebo"
    ],
    "briefSummary": "To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2006-12",
    "completionDate": "2008-02",
    "primaryCompletionDate": "2008-02",
    "firstPostedDate": "2006-12-08",
    "lastUpdatePostedDate": "2011-07-26",
    "locations": [
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Beijing",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Changsha",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Harbin",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Nanjin",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Nanjing",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Shanghai",
        "state": null,
        "country": "China"
      },
      {
        "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
        "city": "Wuhan",
        "state": null,
        "country": "China"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT00408993",
    "scrapedAt": "2026-05-14T17:51:07.038Z"
  },
  {
    "nctId": "NCT01002521",
    "briefTitle": "Wound Healing In Diabetes (WHy) Study",
    "officialTitle": "Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers",
    "acronym": "WHy",
    "organization": "The University of The West Indies",
    "overallStatus": "UNKNOWN",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 605,
    "leadSponsor": "The University of The West Indies",
    "sponsorClass": "OTHER",
    "collaborators": [
      "Chronic Disease Research Centre",
      "Barbados Diabetes Foundation"
    ],
    "conditions": [
      "Impaired Wound Healing",
      "Diabetes Mellitus"
    ],
    "interventions": [],
    "briefSummary": "This observational study aims to identify risk factors and molecular mechanisms of impaired wound healing, to guide better foot care in the diabetic population.",
    "sex": "ALL",
    "minimumAge": null,
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2009-12",
    "completionDate": "2012-06",
    "primaryCompletionDate": "2011-06",
    "firstPostedDate": "2009-10-27",
    "lastUpdatePostedDate": "2009-10-27",
    "locations": [
      {
        "facility": "Chronic Disease Research Centre",
        "city": "Bridgetown",
        "state": "Saint Michael",
        "country": "Barbados"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01002521",
    "scrapedAt": "2026-05-14T17:51:07.083Z"
  },
  {
    "nctId": "NCT00001733",
    "briefTitle": "Screening for Studies on Retinovascular Diseases",
    "officialTitle": "Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases",
    "acronym": null,
    "organization": "National Institutes of Health Clinical Center (CC)",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 2000,
    "leadSponsor": "National Eye Institute (NEI)",
    "sponsorClass": "NIH",
    "collaborators": [],
    "conditions": [
      "Diabetic Retinopathy",
      "Macular Degeneration",
      "Pathologic Neovascularization",
      "Retinal Disease"
    ],
    "interventions": [],
    "briefSummary": "This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease study.\n\nCandidates will undergo a medical history and comprehensive eye examination. The eye examination includes dilation of the pupils to fully examine the retina. In some studies, photographs of the eye are required. This is done using fluorescein angiography. In this procedure, a dye called sodium fluorescein is injected into the blood stream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Other diagnostic procedures may include physical examination, questionnaires, routine laboratory tests and other standard or specialized tests, as needed.\n\nWhen the screening is completed, patients will be informed of their options to participate in a study. Patients who are ineligible for a current study will be informed of alternative treatments or options. No treatment is offered under this protocol.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": true,
    "startDate": "1998-03-06",
    "completionDate": "2008-07-02",
    "primaryCompletionDate": null,
    "firstPostedDate": "1999-11-04",
    "lastUpdatePostedDate": "2017-07-02",
    "locations": [
      {
        "facility": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
        "city": "Bethesda",
        "state": "Maryland",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00001733",
    "scrapedAt": "2026-05-14T17:51:07.102Z"
  },
  {
    "nctId": "NCT07075133",
    "briefTitle": "Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes",
    "officialTitle": "Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes",
    "acronym": "TIMEDIAB",
    "organization": "University Hospital, Toulouse",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 45,
    "leadSponsor": "University Hospital, Toulouse",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Obesity",
      "Sarcopenia",
      "Post Menopause",
      "Type 2 Diabetes",
      "Circadian Clock"
    ],
    "interventions": [
      "OTHER: Antidiabetic diet (control)",
      "OTHER: eTRE diet",
      "OTHER: Physical activity in the morning",
      "OTHER: Physical activity in the afternoon"
    ],
    "briefSummary": "The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint",
    "sex": "ALL",
    "minimumAge": "45 Years",
    "maximumAge": "70 Years",
    "healthyVolunteers": true,
    "startDate": "2025-07-15",
    "completionDate": "2029-07-15",
    "primaryCompletionDate": "2029-07-15",
    "firstPostedDate": "2025-07-20",
    "lastUpdatePostedDate": "2025-07-20",
    "locations": [
      {
        "facility": "Rangueil Hospital",
        "city": "Toulouse",
        "state": "France",
        "country": "France"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07075133",
    "scrapedAt": "2026-05-14T17:51:07.140Z"
  },
  {
    "nctId": "NCT04213547",
    "briefTitle": "Sleep and Glycemic Control in Type 2 Diabetes Adolescents",
    "officialTitle": "Sleep Duration and Glycemic Control in Adolescents With Type 2 Diabetes Mellitus",
    "acronym": null,
    "organization": "Children's Hospital of Philadelphia",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 90,
    "leadSponsor": "Children's Hospital of Philadelphia",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)"
    ],
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "BEHAVIORAL: Loss frame sleep extension intervention"
    ],
    "briefSummary": "The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \\<8 hr sleep/evening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.",
    "sex": "ALL",
    "minimumAge": "12 Years",
    "maximumAge": "20 Years",
    "healthyVolunteers": false,
    "startDate": "2020-09-16",
    "completionDate": "2026-06-01",
    "primaryCompletionDate": "2026-06-01",
    "firstPostedDate": "2019-12-30",
    "lastUpdatePostedDate": "2026-04-03",
    "locations": [
      {
        "facility": "Children's Hospital of Philadelphia",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04213547",
    "scrapedAt": "2026-05-14T17:51:07.166Z"
  },
  {
    "nctId": "NCT00534547",
    "briefTitle": "Duodenal Exclusion for the Treatment of Type 2 Diabetes",
    "officialTitle": "Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)",
    "acronym": null,
    "organization": "Medtronic - MITG",
    "overallStatus": "WITHDRAWN",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 0,
    "leadSponsor": "Medtronic - MITG",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes"
    ],
    "interventions": [
      "PROCEDURE: Duodenal Exclusion"
    ],
    "briefSummary": "The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "50 Years",
    "healthyVolunteers": false,
    "startDate": null,
    "completionDate": null,
    "primaryCompletionDate": null,
    "firstPostedDate": "2007-09-26",
    "lastUpdatePostedDate": "2015-07-27",
    "locations": [],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00534547",
    "scrapedAt": "2026-05-14T17:51:07.241Z"
  },
  {
    "nctId": "NCT07385547",
    "briefTitle": "Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency",
    "officialTitle": "A Phase 1 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of GL0034",
    "acronym": null,
    "organization": "Sun Pharmaceutical Industries Limited",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "enrollmentCount": 40,
    "leadSponsor": "Sun Pharmaceutical Industries Limited",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Type II Diabetes Mellitus"
    ],
    "interventions": [
      "DRUG: GL0034"
    ],
    "briefSummary": "This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": true,
    "startDate": "2026-02-25",
    "completionDate": "2026-09-27",
    "primaryCompletionDate": "2026-09",
    "firstPostedDate": "2026-02-04",
    "lastUpdatePostedDate": "2026-03-13",
    "locations": [
      {
        "facility": "Syneos Miami",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Panax Clinical Research",
        "city": "Miami Lakes",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "Orlando Clinical Research Center (OCRC)",
        "city": "Orlando",
        "state": "Florida",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07385547",
    "scrapedAt": "2026-05-14T17:51:07.279Z"
  },
  {
    "nctId": "NCT00806858",
    "briefTitle": "Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus",
    "officialTitle": "NovoPen®4 Clinical Experience Programme: A Multicentre, Observational Study of NovoPen®4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus",
    "acronym": null,
    "organization": "Novo Nordisk A/S",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 526,
    "leadSponsor": "Novo Nordisk A/S",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Delivery Systems"
    ],
    "interventions": [
      "DEVICE: NovoPen® 4"
    ],
    "briefSummary": "This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.",
    "sex": "ALL",
    "minimumAge": null,
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2008-11",
    "completionDate": "2009-07",
    "primaryCompletionDate": "2009-07",
    "firstPostedDate": "2008-12-11",
    "lastUpdatePostedDate": "2016-11-23",
    "locations": [
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Beijing",
        "state": "Beijing Municipality",
        "country": "China"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00806858",
    "scrapedAt": "2026-05-14T17:51:07.298Z"
  },
  {
    "nctId": "NCT01943357",
    "briefTitle": "Improving Self Management Skills of Older Adults With Diabetes",
    "officialTitle": "Improving the Self Management Skills of Older Adults With Diabetes",
    "acronym": null,
    "organization": "Stanford University",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 1000,
    "leadSponsor": "Stanford University",
    "sponsorClass": "OTHER",
    "collaborators": [
      "HealthCore, Inc."
    ],
    "conditions": [
      "Type 2 Diabetes",
      "Diabetes"
    ],
    "interventions": [
      "BEHAVIORAL: Diabetes Self Management Program"
    ],
    "briefSummary": "The study will help determine if the Better Choices Better Health Diabetes program (community-based or online, also known as the Diabetes Self-Management Program) improves the hbA1C of people with Type-II diabetes. The investigators will also examine 1) symptoms (fatigue, sleep, low blood sugar symptoms, depression, shortness of breath), 2) healthy behaviors (blood sugar monitoring; taking medications as prescribed; getting eye, foot, kidney and cholesterol exams; and activity), 3) the use of health care services. This project is a translational study to demonstrate the effectiveness of the intervention in the context of a major insurer.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2013-09",
    "completionDate": "2017-02",
    "primaryCompletionDate": "2016-03",
    "firstPostedDate": "2013-09-16",
    "lastUpdatePostedDate": "2017-04-25",
    "locations": [
      {
        "facility": "Stanford University School of Medicine",
        "city": "Stanford",
        "state": "California",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT01943357",
    "scrapedAt": "2026-05-14T17:51:07.318Z"
  },
  {
    "nctId": "NCT00278057",
    "briefTitle": "STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE",
    "officialTitle": "PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS.",
    "acronym": null,
    "organization": "Regional Hospital Holstebro",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "enrollmentCount": 55,
    "leadSponsor": "Regional Hospital Holstebro",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Hemodialysis"
    ],
    "interventions": [
      "DRUG: dialysisis with and without glucose in the dialysis"
    ],
    "briefSummary": "We wanted to test the hypotheses that blood pressure level was lower, that the variability of blood pressure and blood glucose was reduced, and that quality of life was improved when glucose was added to the dialysis fluid.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2003-05",
    "completionDate": "2003-05",
    "primaryCompletionDate": null,
    "firstPostedDate": "2006-01-18",
    "lastUpdatePostedDate": "2006-01-18",
    "locations": [
      {
        "facility": "Department of Medicine, Holstebro Hospital",
        "city": "Holstebro",
        "state": null,
        "country": "Denmark"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT00278057",
    "scrapedAt": "2026-05-14T17:51:07.334Z"
  },
  {
    "nctId": "NCT02356757",
    "briefTitle": "Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy",
    "officialTitle": "Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy",
    "acronym": "PATRIOT",
    "organization": "VA Office of Research and Development",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 406,
    "leadSponsor": "VA Office of Research and Development",
    "sponsorClass": "FED",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Foot Ulcer"
    ],
    "interventions": [
      "BEHAVIORAL: Personalized Behavioral Intervention",
      "BEHAVIORAL: Current Best Practice"
    ],
    "briefSummary": "The PATRIOT study will evaluate a risk-based personalized behavioral intervention to improve foot self-care, self-monitoring, and modifiable risks for amputation such as blood glucose, blood pressure and cholesterol in order to prevent diabetic foot ulcers in patients at higher than normal risk for amputation. This novel intervention aims to improve self-care and early detection of foot abnormalities in at-risk patients with diabetes and poor foot self-care using advanced behavioral approaches to target adherence to multiple health behaviors, including foot self-care, self-monitoring, medication adherence, dietary adherence, and physical activity simultaneously. If this promising behavioral theory-driven approach delivered using common technology (phone) to the patient at home can work in a setting where improvements in foot care are so urgent, it will be an important scientific contribution.",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2015-08-24",
    "completionDate": "2021-09-30",
    "primaryCompletionDate": "2021-06-30",
    "firstPostedDate": "2015-02-05",
    "lastUpdatePostedDate": "2021-10-22",
    "locations": [
      {
        "facility": "Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT02356757",
    "scrapedAt": "2026-05-14T17:51:07.367Z"
  },
  {
    "nctId": "NCT01194830",
    "briefTitle": "Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study",
    "officialTitle": "A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study",
    "acronym": null,
    "organization": "Boehringer Ingelheim",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 234,
    "leadSponsor": "Boehringer Ingelheim",
    "sponsorClass": "INDUSTRY",
    "collaborators": [
      "Eli Lilly and Company"
    ],
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: Linagliptin",
      "DRUG: Placebo"
    ],
    "briefSummary": "Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2010-09",
    "completionDate": "2011-10",
    "primaryCompletionDate": "2011-10",
    "firstPostedDate": "2010-09-03",
    "lastUpdatePostedDate": "2014-01-29",
    "locations": [
      {
        "facility": "1218.75.059 Boehringer Ingelheim Investigational Site",
        "city": "Birmingham",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "1218.75.054 Boehringer Ingelheim Investigational Site",
        "city": "Huntsville",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "1218.75.035 Boehringer Ingelheim Investigational Site",
        "city": "Mobile",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "1218.75.101 Boehringer Ingelheim Investigational Site",
        "city": "Toney",
        "state": "Alabama",
        "country": "United States"
      },
      {
        "facility": "1218.75.066 Boehringer Ingelheim Investigational Site",
        "city": "Little Rock",
        "state": "Alaska",
        "country": "United States"
      },
      {
        "facility": "1218.75.008 Boehringer Ingelheim Investigational Site",
        "city": "Pell City",
        "state": "Alaska",
        "country": "United States"
      },
      {
        "facility": "1218.75.071 Boehringer Ingelheim Investigational Site",
        "city": "Anaheim",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "1218.75.018 Boehringer Ingelheim Investigational Site",
        "city": "Chino",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "1218.75.081 Boehringer Ingelheim Investigational Site",
        "city": "Garden Grove",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "1218.75.109 Boehringer Ingelheim Investigational Site",
        "city": "Los Angeles",
        "state": "California",
        "country": "United States"
      },
      {
        "facility": "1218.75.040 Boehringer Ingelheim Investigational Site",
        "city": "Colorado Springs",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "1218.75.047 Boehringer Ingelheim Investigational Site",
        "city": "Denver",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "1218.75.106 Boehringer Ingelheim Investigational Site",
        "city": "Bartow",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.098 Boehringer Ingelheim Investigational Site",
        "city": "Bradenton",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.036 Boehringer Ingelheim Investigational Site",
        "city": "Chiefland",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.105 Boehringer Ingelheim Investigational Site",
        "city": "Fort Lauderdale",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.083 Boehringer Ingelheim Investigational Site",
        "city": "Fort Myers",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.002 Boehringer Ingelheim Investigational Site",
        "city": "Hialeah",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.080 Boehringer Ingelheim Investigational Site",
        "city": "Jacksonville",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.065 Boehringer Ingelheim Investigational Site",
        "city": "Jupiter",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.007 Boehringer Ingelheim Investigational Site",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.029 Boehringer Ingelheim Investigational Site",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.045 Boehringer Ingelheim Investigational Site",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.084 Boehringer Ingelheim Investigational Site",
        "city": "Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.017 Boehringer Ingelheim Investigational Site",
        "city": "Ocala",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.012 Boehringer Ingelheim Investigational Site",
        "city": "Pinellas Park",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.074 Boehringer Ingelheim Investigational Site",
        "city": "Port Orange",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.076 Boehringer Ingelheim Investigational Site",
        "city": "South Miami",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.003 Boehringer Ingelheim Investigational Site",
        "city": "St. Petersburg",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.039 Boehringer Ingelheim Investigational Site",
        "city": "St. Petersburg",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.075 Boehringer Ingelheim Investigational Site",
        "city": "Tallahassee",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.100 Boehringer Ingelheim Investigational Site",
        "city": "Tamarac",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.015 Boehringer Ingelheim Investigational Site",
        "city": "Tampa",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.103 Boehringer Ingelheim Investigational Site",
        "city": "West Palm Beach",
        "state": "Florida",
        "country": "United States"
      },
      {
        "facility": "1218.75.049 Boehringer Ingelheim Investigational Site",
        "city": "Atlanta",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.067 Boehringer Ingelheim Investigational Site",
        "city": "Calhoun",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.016 Boehringer Ingelheim Investigational Site",
        "city": "Dunwoody",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.063 Boehringer Ingelheim Investigational Site",
        "city": "Lawrenceville",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.056 Boehringer Ingelheim Investigational Site",
        "city": "Marietta",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.026 Boehringer Ingelheim Investigational Site",
        "city": "Rosswell",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.079 Boehringer Ingelheim Investigational Site",
        "city": "Sandy Springs",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.034 Boehringer Ingelheim Investigational Site",
        "city": "Snellville",
        "state": "Georgia",
        "country": "United States"
      },
      {
        "facility": "1218.75.001 Boehringer Ingelheim Investigational Site",
        "city": "Chicago",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "1218.75.055 Boehringer Ingelheim Investigational Site",
        "city": "Chicago",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "1218.75.069 Boehringer Ingelheim Investigational Site",
        "city": "Owensboro",
        "state": "Kentucky",
        "country": "United States"
      },
      {
        "facility": "1218.75.044 Boehringer Ingelheim Investigational Site",
        "city": "Baton Rouge",
        "state": "Louisiana",
        "country": "United States"
      },
      {
        "facility": "1218.75.108 Boehringer Ingelheim Investigational Site",
        "city": "Essex",
        "state": "Maryland",
        "country": "United States"
      },
      {
        "facility": "1218.75.086 Boehringer Ingelheim Investigational Site",
        "city": "Brockton",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "1218.75.087 Boehringer Ingelheim Investigational Site",
        "city": "Watertown",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "1218.75.051 Boehringer Ingelheim Investigational Site",
        "city": "Detroit",
        "state": "Michigan",
        "country": "United States"
      },
      {
        "facility": "1218.75.088 Boehringer Ingelheim Investigational Site",
        "city": "Flint",
        "state": "Michigan",
        "country": "United States"
      },
      {
        "facility": "1218.75.099 Boehringer Ingelheim Investigational Site",
        "city": "Biloxi",
        "state": "Mississippi",
        "country": "United States"
      },
      {
        "facility": "1218.75.006 Boehringer Ingelheim Investigational Site",
        "city": "Atco",
        "state": "New Jersey",
        "country": "United States"
      },
      {
        "facility": "1218.75.004 Boehringer Ingelheim Investigational Site",
        "city": "Camden",
        "state": "New Jersey",
        "country": "United States"
      },
      {
        "facility": "1218.75.031 Boehringer Ingelheim Investigational Site",
        "city": "Brooklyn",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "1218.75.095 Boehringer Ingelheim Investigational Site",
        "city": "Brooklyn",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "1218.75.038 Boehringer Ingelheim Investigational Site",
        "city": "Asheboro",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.009 Boehringer Ingelheim Investigational Site",
        "city": "Charlotte",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.023 Boehringer Ingelheim Investigational Site",
        "city": "Charlotte",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.060 Boehringer Ingelheim Investigational Site",
        "city": "Charlotte",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.005 Boehringer Ingelheim Investigational Site",
        "city": "Greensboro",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.107 Boehringer Ingelheim Investigational Site",
        "city": "High Point",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.020 Boehringer Ingelheim Investigational Site",
        "city": "Jacksonville",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.027 Boehringer Ingelheim Investigational Site",
        "city": "Winston-Salem",
        "state": "North Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.096 Boehringer Ingelheim Investigational Site",
        "city": "Akron",
        "state": "Ohio",
        "country": "United States"
      },
      {
        "facility": "1218.75.090 Boehringer Ingelheim Investigational Site",
        "city": "Columbus",
        "state": "Ohio",
        "country": "United States"
      },
      {
        "facility": "1218.75.078 Boehringer Ingelheim Investigational Site",
        "city": "Dayton",
        "state": "Ohio",
        "country": "United States"
      },
      {
        "facility": "1218.75.037 Boehringer Ingelheim Investigational Site",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "1218.75.082 Boehringer Ingelheim Investigational Site",
        "city": "Philadelphia",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "1218.75.010 Boehringer Ingelheim Investigational Site",
        "city": "Uniontown",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "1218.75.028 Boehringer Ingelheim Investigational Site",
        "city": "Uniontown",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "1218.75.091 Boehringer Ingelheim Investigational Site",
        "city": "Anderson",
        "state": "South Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.072 Boehringer Ingelheim Investigational Site",
        "city": "Columbia",
        "state": "South Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.068 Boehringer Ingelheim Investigational Site",
        "city": "Greenwood",
        "state": "South Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.097 Boehringer Ingelheim Investigational Site",
        "city": "Greer",
        "state": "South Carolina",
        "country": "United States"
      },
      {
        "facility": "1218.75.024 Boehringer Ingelheim Investigational Site",
        "city": "Brentwood",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.025 Boehringer Ingelheim Investigational Site",
        "city": "Collierville",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.011 Boehringer Ingelheim Investigational Site",
        "city": "Germantown",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.042 Boehringer Ingelheim Investigational Site",
        "city": "Humboldt",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.030 Boehringer Ingelheim Investigational Site",
        "city": "Memphis",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.050 Boehringer Ingelheim Investigational Site",
        "city": "Memphis",
        "state": "Tennessee",
        "country": "United States"
      },
      {
        "facility": "1218.75.053 Boehringer Ingelheim Investigational Site",
        "city": "Dallas",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.057 Boehringer Ingelheim Investigational Site",
        "city": "Houston",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.064 Boehringer Ingelheim Investigational Site",
        "city": "Houston",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.104 Boehringer Ingelheim Investigational Site",
        "city": "Houston",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.043 Boehringer Ingelheim Investigational Site",
        "city": "Houton",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.022 Boehringer Ingelheim Investigational Site",
        "city": "San Antonio",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.058 Boehringer Ingelheim Investigational Site",
        "city": "Sugar Land",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.033 Boehringer Ingelheim Investigational Site",
        "city": "Tomball",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.102 Boehringer Ingelheim Investigational Site",
        "city": "Tomball",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.094 Boehringer Ingelheim Investigational Site",
        "city": "Waco",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.092 Boehringer Ingelheim Investigational Site",
        "city": "Whitney",
        "state": "Texas",
        "country": "United States"
      },
      {
        "facility": "1218.75.019 Boehringer Ingelheim Investigational Site",
        "city": "Virgnia Beach",
        "state": "Virginia",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT01194830",
    "scrapedAt": "2026-05-14T17:51:07.385Z"
  },
  {
    "nctId": "NCT05205928",
    "briefTitle": "Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care",
    "officialTitle": "Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial",
    "acronym": "SEMA-AP",
    "organization": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "enrollmentCount": 28,
    "leadSponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes",
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "DRUG: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy"
    ],
    "briefSummary": "A closed-loop insulin system, also referred to as the \"artificial pancreas\" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration based on glucose control. This is meant for the treatment of type 1 diabetes. The McGill Artificial Pancreas (MAP) has been used previously in type 1 diabetes with significant benefits. Though prior studies have shown significant benefit with this system, some challenges still exist.\n\nSemaglutide is used in type 2 diabetes and obesity; it is a once-weekly injectable medication that increases levels of a gut hormone called Glucagon-Like Peptide-1, which modifies gastric emptying, suppresses glucagon, and suppresses appetite. Though its use is not approved in type 1 diabetes in North America, it (along with similar drugs) has been used in studies as adjunctive therapy with insulin with benefits on blood sugar control. Similar medications have been used in type 1 diabetes (such as liraglutide and exenatide), but are not as strong in glucose effect even in type 2 diabetes as compared with semaglutide.\n\nThe purpose of our study is to see if semaglutide administered weekly at the maximum tolerated dose in those with type 1 diabetes will have improved glucose control (as per time in target range from continuous glucose monitoring data) compared to placebo, while using a closed-loop insulin system.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2022-10-02",
    "completionDate": "2024-06-30",
    "primaryCompletionDate": "2024-04-15",
    "firstPostedDate": "2022-01-25",
    "lastUpdatePostedDate": "2025-01-22",
    "locations": [
      {
        "facility": "Research Institute of the McGill University Health Centre",
        "city": "Montreal",
        "state": "Quebec",
        "country": "Canada"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT05205928",
    "scrapedAt": "2026-05-14T17:51:07.411Z"
  },
  {
    "nctId": "NCT07560800",
    "briefTitle": "Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes",
    "officialTitle": "Effect of Beetroot Juice on Cardiovascular and Autonomic Responses During and After Exercise in Adults With Type 2 Diabetes",
    "acronym": "DiaBEET",
    "organization": "Oxford Brookes University",
    "overallStatus": "NOT_YET_RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "Oxford Brookes University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes Mellitus",
      "Hypertension",
      "Autonomic Nervous System Diseases"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Beetroot juice",
      "DIETARY_SUPPLEMENT: Nitrate-depleted Beetroot Juice Placebo"
    ],
    "briefSummary": "This study will investigate whether a single dose of beetroot juice can improve cardiovascular responses and recovery after exercise in adults with Type 2 Diabetes.\n\nType 2 Diabetes is associated with higher blood pressure, impaired blood vessel function, and reduced autonomic control of the heart, all of which increase cardiovascular risk and may affect how the body responds to and recovers from physical activity. Beetroot juice is naturally rich in dietary nitrate, which is converted in the body into nitric oxide, a molecule that helps blood vessels relax and improve blood flow. While these effects have been demonstrated in healthy individuals, less is known about their impact in people with Type 2 Diabetes.\n\nIn this study, approximately 16 to 20 adults aged 40 to 65 years with Type 2 Diabetes will take part. After an online screening and consent process, eligible participants will attend two laboratory visits at Oxford Brookes University. In a randomised, double-blind, placebo-controlled crossover design, participants will receive beetroot juice during one visit and a nitrate-depleted placebo during the other visit.\n\nDuring each visit, participants will undergo physiological measurements, including blood pressure, heart rate, oxygen saturation, and capillary blood glucose. Participants will then complete a short session of supervised, light-to-moderate cycling exercise. Measurements will continue during the recovery period to assess how quickly the cardiovascular system returns to resting levels.\n\nThe main outcomes are systolic blood pressure and heart rate variability during recovery, which reflect cardiovascular regulation and autonomic function. Secondary outcomes include diastolic blood pressure, heart rate, blood glucose, and markers related to nitric oxide availability.\n\nThis study may help determine whether a simple, dietary-based intervention such as beetroot juice can support cardiovascular function and improve recovery after exercise in people living with Type 2 Diabetes.",
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "65 Years",
    "healthyVolunteers": false,
    "startDate": "2026-04-02",
    "completionDate": "2026-07-31",
    "primaryCompletionDate": "2026-07-31",
    "firstPostedDate": "2026-05-01",
    "lastUpdatePostedDate": "2026-05-01",
    "locations": [
      {
        "facility": "Clinical Physiology Laboratory, Oxford Brookes University",
        "city": "Oxford",
        "state": "Oxfordshire",
        "country": "United Kingdom"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT07560800",
    "scrapedAt": "2026-05-14T17:51:07.438Z"
  },
  {
    "nctId": "NCT05683392",
    "briefTitle": "Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes",
    "officialTitle": "Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes",
    "acronym": null,
    "organization": "Tandem Diabetes Care, Inc.",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 72,
    "leadSponsor": "Tandem Diabetes Care, Inc.",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "DEVICE: t:slim X2 insulin pump with Control-IQ technology 2.0"
    ],
    "briefSummary": "The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.",
    "sex": "ALL",
    "minimumAge": "2 Years",
    "maximumAge": "80 Years",
    "healthyVolunteers": false,
    "startDate": "2023-02-01",
    "completionDate": "2023-12-13",
    "primaryCompletionDate": "2023-12-13",
    "firstPostedDate": "2023-01-13",
    "lastUpdatePostedDate": "2024-12-20",
    "locations": [
      {
        "facility": "Barbara Davis Center (Pediatric Clinic)",
        "city": "Aurora",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "Barbara Davis Center",
        "city": "Aurora",
        "state": "Colorado",
        "country": "United States"
      },
      {
        "facility": "Joslin Diabetes Center",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "University of Virginia",
        "city": "Charlottesville",
        "state": "Virginia",
        "country": "United States"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT05683392",
    "scrapedAt": "2026-05-14T17:51:07.494Z"
  },
  {
    "nctId": "NCT04860336",
    "briefTitle": "Glycemic Observation and Metabolic Outcomes in Mothers and Offspring",
    "officialTitle": "Glycemic Observation and Metabolic Outcomes in Mothers and Offspring / Glycemic Profile of Pregnancy Consortium",
    "acronym": "GO MOMs",
    "organization": "Northwestern University",
    "overallStatus": "COMPLETED",
    "studyType": "OBSERVATIONAL",
    "phases": [],
    "enrollmentCount": 2179,
    "leadSponsor": "Northwestern University",
    "sponsorClass": "OTHER",
    "collaborators": [
      "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "Yale University",
      "Women and Infants Hospital of Rhode Island",
      "University of Pittsburgh",
      "Massachusetts General Hospital",
      "Tufts Medical Center",
      "Columbia University",
      "Kaiser Permanente"
    ],
    "conditions": [
      "Gestational Diabetes",
      "Pregnancy Related"
    ],
    "interventions": [
      "OTHER: Observational"
    ],
    "briefSummary": "The overarching goal of Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) is to perform a comprehensive, longitudinal description of maternal glycemia over the course of pregnancy and to evaluate how glucose levels throughout pregnancy relate to traditional third trimester gestational diabetes mellitus (GDM) screening and perinatal outcomes.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2021-04-01",
    "completionDate": "2025-07-18",
    "primaryCompletionDate": "2025-06-09",
    "firstPostedDate": "2021-04-26",
    "lastUpdatePostedDate": "2026-04-16",
    "locations": [
      {
        "facility": "Yale University",
        "city": "New Haven",
        "state": "Connecticut",
        "country": "United States"
      },
      {
        "facility": "Kaiser Permanente - Hawaii",
        "city": "Honolulu",
        "state": "Hawaii",
        "country": "United States"
      },
      {
        "facility": "Northwestern University",
        "city": "Chicago",
        "state": "Illinois",
        "country": "United States"
      },
      {
        "facility": "Tufts Medical Center",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "Massachusetts General Hospital",
        "city": "Boston",
        "state": "Massachusetts",
        "country": "United States"
      },
      {
        "facility": "Columbia University",
        "city": "New York",
        "state": "New York",
        "country": "United States"
      },
      {
        "facility": "Kaiser Permanente - Northwest",
        "city": "Portland",
        "state": "Oregon",
        "country": "United States"
      },
      {
        "facility": "Magee Womens Research Institute & Foundation",
        "city": "Pittsburgh",
        "state": "Pennsylvania",
        "country": "United States"
      },
      {
        "facility": "Women and Infants Hospital of Rhode Island",
        "city": "Providence",
        "state": "Rhode Island",
        "country": "United States"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04860336",
    "scrapedAt": "2026-05-14T17:51:07.524Z"
  },
  {
    "nctId": "NCT01880736",
    "briefTitle": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes",
    "officialTitle": "A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes",
    "acronym": null,
    "organization": "Novo Nordisk A/S",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "enrollmentCount": 458,
    "leadSponsor": "Novo Nordisk A/S",
    "sponsorClass": "INDUSTRY",
    "collaborators": [],
    "conditions": [
      "Diabetes",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "DRUG: insulin degludec",
      "DRUG: insulin degludec",
      "DRUG: insulin degludec"
    ],
    "briefSummary": "This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes.",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2013-06",
    "completionDate": "2014-04",
    "primaryCompletionDate": "2014-04",
    "firstPostedDate": "2013-06-19",
    "lastUpdatePostedDate": "2017-02-10",
    "locations": [
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Chuo-ku, Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Chuo-ku, Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Fukui-shi, Fukui",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Gifu-shi, Gifu",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Izumisano",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kagoshima-shi, Kagoshima",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kamakura-shi",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kashiwara-shi, Osaka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Katsushika-ku, Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kawasaki-shi, Kanagawa",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kitakyushu-shi, Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kitakyushu-shi, Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kitakyusyu-shi, Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Koriyama-shi, Fukushima",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Kumamoto-shi,Kumamoto",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Mito-shi, Ibaraki",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Miyazaki",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Naka-shi, Ibaraki",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Niigata-shi, Niigata",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Nishinomiya-shi, Hyogo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Okawa-shi, Fukuoka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Osaka-shi, Osaka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Oyama-shi, Tochigi",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Ōita",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Sakaide-shi, Kagawa",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Sapporo-shi, Hokkaido",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Sapporo-shi, Hokkaido",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Sapporo-shi, Hokkaido",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Sendai",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Shimotsuke-shi, Tochigi",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Suita-shi, Osaka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Takatsuki-shi, Osaka",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Tokyo",
        "state": null,
        "country": "Japan"
      },
      {
        "facility": "Novo Nordisk Investigational Site",
        "city": "Yokkaichi-shi, Mie",
        "state": null,
        "country": "Japan"
      }
    ],
    "hasResults": true,
    "url": "https://clinicaltrials.gov/study/NCT01880736",
    "scrapedAt": "2026-05-14T17:51:07.542Z"
  },
  {
    "nctId": "NCT03942471",
    "briefTitle": "Mindfulness for Adolescents With Type 1 Diabetes",
    "officialTitle": "The Effects of Learning Mindfulness Based Stress Reduction on Psychosocial Variables and HbA1c in Adolescents With Type 1 Diabetes",
    "acronym": null,
    "organization": "Duquesne University",
    "overallStatus": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 65,
    "leadSponsor": "Duquesne University",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "BEHAVIORAL: Mindfulness Based Stress Reduction"
    ],
    "briefSummary": "Adolescents with Type 1 Diabetes will be invited to the Mindfulness study. They will be randomly assigned to a Control or Active Group. The Active Group will learn Mindfulness Based Stress Reduction (MBSR) through an online website designed to teach the basic principles of MBSR in six week-long modules. They will be measured in three main areas: before learning the intervention, directly after learning it and 3 months after learning it to determine any changes in their Mindful attention awareness, Diabetes Quality of Life and HbA1c. The Control Group will also take the questionnaires at the beginning of the study, 6 weeks after it begins and then 3 months from the beginning to obtain data for all three time points when they have not received access to the modules/intervention.",
    "sex": "ALL",
    "minimumAge": "12 Years",
    "maximumAge": "19 Years",
    "healthyVolunteers": false,
    "startDate": "2015-10-14",
    "completionDate": "2019-01-05",
    "primaryCompletionDate": "2018-10-01",
    "firstPostedDate": "2019-05-08",
    "lastUpdatePostedDate": "2019-05-08",
    "locations": [],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT03942471",
    "scrapedAt": "2026-05-14T17:51:07.596Z"
  },
  {
    "nctId": "NCT04917471",
    "briefTitle": "Effect of Nitrate on Red Blood Cell Function in Type 2 Diabetes",
    "officialTitle": "The Effect of Dietary Nitrate Supplementation on Red Blood Cell Function in Patients with Type 2 Diabetes",
    "acronym": null,
    "organization": "Karolinska Institutet",
    "overallStatus": "RECRUITING",
    "studyType": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "enrollmentCount": 20,
    "leadSponsor": "Karolinska Institutet",
    "sponsorClass": "OTHER",
    "collaborators": [],
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "DIETARY_SUPPLEMENT: Beet root juice",
      "DIETARY_SUPPLEMENT: Placebo juice"
    ],
    "briefSummary": "To investigate the effect of nitrate supplementation on red blood cell function in patients with type 2 diabetes.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": null,
    "healthyVolunteers": false,
    "startDate": "2021-06-01",
    "completionDate": "2025-12-31",
    "primaryCompletionDate": "2025-12-30",
    "firstPostedDate": "2021-06-08",
    "lastUpdatePostedDate": "2024-10-09",
    "locations": [
      {
        "facility": "Karolinska Institutet, Karolinska University Hospital",
        "city": "Stockholm",
        "state": null,
        "country": "Sweden"
      }
    ],
    "hasResults": false,
    "url": "https://clinicaltrials.gov/study/NCT04917471",
    "scrapedAt": "2026-05-14T17:51:07.616Z"
  }
]